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ABSTRACT

DEVELOPMENT OF A BEAM-SPECIFIC PLANNING TARGET VOLUME AND A
ROBUST PLAN ANALYSIS TOOLS FOR PROTON THERAPY
Publication No.______
Peter C. Park, B.S.
Supervisory Professor: X. Ronald Zhu, Ph.D
Proton therapy is growing increasingly popular due to its superior dose
characteristics compared to conventional photon therapy. Protons travel a finite range in
the patient body and stop, thereby delivering no dose beyond their range. However,
because the range of a proton beam is heavily dependent on the tissue density along its
beam path, uncertainties in patient setup position and inherent range calculation can
degrade thedose distribution significantly. Despite these challenges that are unique to
proton therapy, current management of the uncertainties during treatment planning of
proton therapy has been similar to that of conventional photon therapy. The goal of this
dissertation research was to develop a treatment planning method and a
planevaluation method that address proton-specific issues regarding setup and
range uncertainties.
Treatment plan designing method adapted to proton therapy: Currently, for
proton therapy using a scanning beam delivery system, setup uncertainties are largely
accounted for by geometrically expanding a clinical target volume (CTV) to a planning
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target volume (PTV). However, a PTV alone cannot adequately account for range
uncertainties coupled to misaligned patient anatomy in the beam path since it does not
account for the change in tissue density. In order to remedy this problem, we proposed a
beam-specific PTV (bsPTV) that accounts for the change in tissue density along the
beam path due to the uncertainties. Our proposed method was successfully implemented,
and its superiority over the conventional PTV was shown through a controlled
experiment.. Furthermore, we have shown that the bsPTV concept can be incorporated
into beam angle optimization for better target coverage and normal tissue sparing for a
selected lung cancer patient.
Treatment plan evaluation method adapted to proton therapy: The dose-volume
histogram of the clinical target volume (CTV) or any other volumes of interest at the
time of planning does not represent the most probable dosimetric outcome of a given
plan as it does not include the uncertainties mentioned earlier. Currently, the PTV is
used as a surrogate of the CTV’s worst case scenario for target dose estimation.
However, because proton dose distributions are subject to change under these
uncertainties, the validity of the PTV analysis method is questionable. In order to
remedy this problem, we proposed the use of statistical parameters to quantify
uncertainties on both the dose-volume histogram and dose distribution directly. The
robust plan analysis tool was successfully implemented to compute both the expectation
value and its standard deviation of dosimetric parameters of a treatment plan under the
uncertainties. For 15 lung cancer patients, the proposed method was used to quantify the
dosimetric difference between the nominal situation and its expected value under the
uncertainties.
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CHAPTER I: INTRODUCTION TO PROTON THERAPY AND ITS
UNCERTAINTIES
A. Background
A.1. Introduction to proton therapy
The concept of treating a tumor using protons was first proposed by Robert R.
Wilson at the Harvard Cyclotron Laboratory in 1946 (1). Wilson pointed out that
because of the relatively heavier mass of a proton, its track in tissue would be straighter
than an electron and its finite range could be utilized to deliver most of its dose at the
end of the range. This would produce a clinically desired dose distribution. The depth
dose curve of mono-energetic protons is often described using the Bragg curve. When
protons interact with a medium, it deposits relatively low dose in the entrance region;
however, as it reaches the end of its range, a substantial amount of dose is deposited
before the dose quickly falls to zero. (See figure 1-1).

Figure 1-1 Concept art depicting the depth dose profile of a proton pencil
beam (the Bragg curve). The Bragg curve shows a relatively low entrance
dose and reaches its maximum dose at the end of its range (the Bragg peak).
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Soon after Wilson’s proposal, the first proton patient was treated in 1950 (2). Following
this, the clinical use of protons began to spread across the high energy physics facilities
(3). With the advancement of technology in manufacturing particle accelerators,
hospital-based proton therapy facilities began to be implemented in the early 1990s (4).
Since then, the number of hospital-based proton therapy facilities in the world grew
exponentially. As of 2012, there are 33 proton facilities world-wide and 10 proton
facilities in the United States with many more facilities planned to be in operation soon
(5).
Table 1-1 Proton therapy facilities as in the United States:
Institution
Loma Linda
Indiana University
Massachusetts General Hospital
MD Anderson Cancer Center, Houston
University of Florida Proton Therapy Institute
ProCure, OK
University of Pennsylvania
Procure/Central Dupage Hospital
Hampton University
ProCure, NJ
ProCure, WA
St. Jude Children’s Research Hospital
Provision Center for Proton Therapy
MD Anderson Cancer Center, Orlando
Barnes Jewish Hospital
University Hospital Case Medical Center
Scripps Health
Mayo Clinics
Mayo Clinics
Mclaren Health Care

Location
CA
IN
MA
TX
FL
OK
PA
IL
VA
NJ
WA
TN
TN
FL
MO
OH
CA
AZ
MN
MI

*This list is not exhaustive.

Start Year
1990
2004
2001
2006
2006
2009
2010
2010
2010
2012
Planned (2013)
Planned (2015)
Planned (2014)
Planned (2014)
Planned (2013)
Planned (2014)
Planned (2013)
Planned (2014)
Planned (2014)
Planned (2013)
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Unlike photons, protons are charged particles that interact with matter through
Coulomb electric force with the electrons and nucleus of the medium they traverse.
Protons with high kinetic energy (i.e. 100 MeV or higher) may undergo nuclear
interactions with contribution of up to 5%of the total dose on the proximal region of the
Bragg curve and up to 1% at the distal end (6). The energy of protons passing through
the medium is lost through successive collisions by transferring fractions of its initial
kinetic energy until it loses all of its initial energy. The expectation value of the rate of


energy loss per unit path length  is called stopping power   and has units of 



.

In general, the stopping power of protons depends on the electron density and meanexcitation energy of the medium and the velocity of the protons.

The relativistic

description of the stopping power is given by the Bethe formula:


  






·

 






   

 

·    


 !

(Eq.1)

where, ! is the fraction of proton’s velocity over the constant speed of light, " is the
energy of the proton,  is the distance travelled by the proton, # is the charge of the
proton, $% is the rest mass of the proton,  is the electron density of the medium, & is
mean excitation potential of the medium, and '( is the permittivity. The shape of the
Bragg curve (i.e. sharp increase in dose at the end of range) is a consequence of the fact
that the stopping power is inversely proportional to the 2nd power of velocity of protons


() !   * ) (7). The precise value of stopping powers for various tissue materials is
of significant value to proton therapy as it is closely related to the proton range. It
should be noted that the range of protons is a stochastic quantity. The precise range of
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each proton in a beam of mono-energetic protons is not easy to determine and is not
necessary for the purpose of radiation therapy. However, the mean path length of the
proton beam must be precisely determined in order to place the Bragg peak at the
intended position within the patient. The range of the proton beam can be formally
defined as the expectation value of path length of protons of same initial energy. In
practice, the range of protons of a mono-energetic beam is closely approximated using
the continuously slowing down approximation (CSDA), which assumes the rate of
energy loss at every point along the track is equal to the total stopping power. The range
based on CDSA (+,-./ can be computed as follows:
4



+,-./  05  1 



3"

(Eq.2)

where 6 is the density of medium and 7( is the initial energy of the protons. The
expected difference between the formal definition of proton range and +,-./ is less
than 0.2% for protons. For practical purposes of dose calculation and other uses, the
formal definition of proton range is replaced by the +,-./ (8).
The theoretical advantage of having the depth dose profile of Bragg curve is that
when protons are precisely targeted to a tumor, it delivers majority of its dose to the
tumor while sparing normal tissue proximal to the target and delivers no dose beyond
the target. However, a single Bragg curve cannot cover a typical target size. In order to
deliver a uniform dose to a large target volume, the range of protons are modulated to
smear the Bragg peak in the depth direction just enough to cover the extent of the target
width (9). This so called the spread-out Bragg peak (SOBP) is simply the sum of many
mono-energetic Bragg peaks of different energies and intensities entering patient body
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(See figure 1-2). There are two distinct types of beam delivery methods in proton
therapy: passively-scattered beam and active-scanning beam. For passively-scattered
beam delivery, the proton beam is broadened laterally using a scattering system and the
SOBP can be obtained by employing a device called a range modulator wheel (RMW)
(See figure 1-3). Protons with the maximum energy required to penetrate the maximum
depth are forced to pass through the rotating RMW, which has varying segment
thickness, thereby pulling some of the protons range proximally (10). For activescanning beam delivery, magnets are used to steer a narrow proton beam laterally and
the SOBP can be obtained by varying the initial energy of protons exiting accelerator
directly (11). The details of the difference between passively-scattered and activescanning beam delivery methods will be discussed in section A.3.Regardless of the
beam delivery method, it is of great importance in proton therapy to precisely place the
SOBP on a target. Particularly the distal fall off of SOBP must conform to the distal
surface of the target to deliver intended dose and to ensure no unnecessary dose is
delivered beyond the target. The advantage of protons having a sharp distal fall off dose
profile can also be a problem since it is less forgiving when the range of proton beam
does not match the range of the distal target volume. Many uncertainties exist related to
the proton beam delivery process that needs to be taken into account and evaluated
carefully in order to achieve the desired clinical outcomes.

6

Figure 1-2 SOBP (red) is simply the sum of many mono-exegetic Bragg peaks
(blue). Due to the summation of proximal dose from many Bragg peaks, the
entrance dose given by the SOBP is significantly higher than a pristine peak.
However, the comparison with the depth dose profile of 10MV photon (black)
still shows the clear advantage of proton beams.

Figure 1-3 An example of a range modulator wheel (RMW) for passivelyscattered proton therapy.
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A.2. Source of uncertainties in proton therapy
Radiotherapy is a complicated process involving many procedures ranging from
delineation of the target volume to beam delivery on the treatment couch. Each of these
procedures carries sources of uncertainty. The most prominent sources of uncertainty
are from target delineation (12), geometric miss of the target due to patient setup and
internal motion error (13, 14), anatomical deformation due to tumor shape change and
patient weight loss (15), and the inability to calculate and deliver dose accurately (16).
All of these sources of uncertainty are common in all types of external beam
radiotherapy. However, the impact of these uncertainties on the delivered dose
distribution to a patient is likely to be greater for proton therapy than conventional
photon therapy for two major reasons. First, as discussed earlier, the chief advantage of
proton therapy is its ability to conform to the target closely. However, this also means
that it is less forgiving if the target is missed. Secondly, the range of protons heavily
depends on the density of the medium it traverses. Any errors that alter the tissue
density of patient with respect to the original setting can significantly deteriorate the
intended dose distribution because the range of proton is a function of the stopping
power ratio of the tissue it travels through (17). Understanding and reducing each of
these uncertainties are the major forefronts of current research effort in the medical
physics community. In this research, our focus will be limited to using existing
knowledge to deal with setup and proton range uncertainties practically.
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A.2.1 Range uncertainty
In order to fully utilize the advantage of proton therapy, a precise determination
of the required proton range to the target is crucial. The proton range in any medium
can be converted to its equivalent range in water. For the convenience of relating proton
ranges in different materials, and because most of beam commissioning data collection
is done in water, it is useful to speak of the proton range as water-equivalent thickness
(WET). For example, protons with same initial energy will have different ranges in
materials of different densities but their WET will be the same. Once the WET is
calculated, the initial energy of protons required to penetrate the depth of a target can be
determined. To calculate WET, we need to know all of the materials that the proton
beam passes through in order to reach the required depth in the patient (see figure 1-4).
Depending on the beam delivery method, the correct combination of beam modifying
devices such as RMW, aperture, compensator and energy absorber of known density
needs to be included.

Figure 1-4 The initial energy of proton beam or WET is calculated based on
the depth required to penetrate the beam modifying devices and patient tissue
density.

9

A WET corresponding to a specific line segment that extends from a source to a
specific point in a target volume can be calculated from a line integral of relative
stopping power ratio (89: (18) as follow:
. %@A

;"7,=  0-(BC 89: , >, ? 3?

(Eq.3)

where the 89:, >, ? is defined by:
1 -G
89:, >, ?  D 1E E
H
G
F

-F ,=,I

(Eq.4)

G are the mean proton mass stopping power
with 6 , 6J are the mass density and KG , KJ
at (, >, ?) of the medium and water respectively (19). In order to determine the 89: of a
given medium at a particular point in space, it is necessary to determine KG. In theory, KG

can be derived using the Bethe formula (Eq.1) if the complete information regarding the
material’s electron density, elemental composition, and mean excitation energy are
known. However, currently there is no straight forward way to obtain this information
for any given tissue element in the patient. In practice, for the purpose of treatment
planning and dose calculation, the 89: of the patient body is approximated from the
patient’s planning CT images by using a calibration curve that establishes a one-to-one
relationship between CT Hounsfield Unit (HU) numbers to the 89: (See figure 1-5).
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Figure 1-5 An example of calibration curve that maps CT HU numbers to
relative stopping power ratio (89: of a planning CT images.

The CT HU number is defined as:
LM 

OOOOON
NE OOOO
F
OOOO
NF

P 1000

(Eq.5)

SJ are the mean photon linear attenuation coefficients of the medium and
where S
OOOO and OOOO
water averaged over the x-ray spectrum of CT. S
OOOO is in turn a function of electron
density ( 6 ) and effective atomic numbers of the material ( ?̃ for photo electric
interaction and ?̂ for coherent scattering). For example, Schneider et al 1997 suggested
following model to be used:
OOOO  6 V %A ?̃ W.Y Z V
S

?̂

(A .[Y

Z V \]

(Eq.6)
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whereV %A , V %A , ^3 V %A are constants describing the photoelectric interaction, coherent
scattering, and Compton scattering (20). The most widely used method of generating a
calibration curve is called the stoichiometric method proposed by Schneider et al in
1996 (21). In this stoichiometric method, CT HU number of selected tissue human
substitutes are calculated based on CT HU modeling parameters (i.e. rather than directly
measuring them) that are uniquely determined for the CT scanner. Although both CT
HU number and the 89: are predominantly governed by the electron density of the
material, from Eq.2 it is clear that there are other variables governing the value of 89:
that are missing from Eq.6. This results in degeneracy of the 89: values for a given CT
HU number. In other words, human tissues with different proton stopping power can
have the same CT HU number. Furthermore, there are many uncertainties in the values
used to model or calculate both the 89: and the CT HU numbers of human tissue
substitutes, resulting in overall inherent uncertainty in our ability to calculate the proton
range in the patient (22).
Recently, Yanget al. (23) performed a comprehensive uncertainty analysis of
calibration curves generated using the stoichiometric method and found that the
uncertainties in 89: values for different tissue type ranges from 5%, 1.6%, and 2.4% for
lung-like, soft, and bone-like tissues. In this study, the authors concluded that when
considering a typical patient of mixed tissue types, the overall proton range error is 3.03.4% (See Table 1-2). In this work, we will assume that most of all range error due to
the inherent uncertainties in the calibration curve to be within 3% to 3.5% of the total
proton range in WET.

12

Table 1-2 Sources of error contributing to the inherent proton range uncertainty.
Sources of error
CT Image
Stoichiometric Formulation
Tissue composition data
Mean excitation energies
Energy spectra of scanner
Total (RMS)
Total (RMS) for composite tissue

Lung (%)
3.3
3.8
0.2
0.2
0.2
5

Soft (%)
0.6
0.8
1.2
0.2
0.2
1.6
3.0-3.4

Bone (%)
1.5
0.5
1.6
0.6
0.4
2.4

A.2.2 Setup uncertainty
Another type of uncertainty that will be considered in this research is setup
uncertainty. Patient setup error results in a geographic miss of some fraction of the
target volume that can occur during registration of the external surface markers attached
to the patient or during registration of soft-tissue or bony landmark under imageguidance. During the treatment planning process, the beam’s isocenter is defined
relative tothe position of the target volume. Based on this geographical configuration,
the beam is shaped and dose distribution is optimized. Therefore, it is crucial that the
position of the target volume remains identical throughout the course of a multifractionated treatment (24). Setup error can be divided into two sub-categories:
systematic and random setup error. In this work, a systematic setup error is defined as
the error that is committed during treatment simulation and therefore gets carried over
the entire course of a multi-fractionated treatment. Some examples of sources of
systematic changes include a change in landmark position in patient, change in
treatment room, and change in patient positioning devices. Random setup error,
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however, is not committed consistently over the course of treatment, but its value varies
from fraction-to-fraction. Because of this, random error cannot be avoided as it is
similar to the natural uncertainty that arises from repeated measurements. However,
random setup errors can be minimized by implementing processes to ensure a more
consistent setup in between fractions. In general, the magnitude of setup error depends
on many factors such as the image-guidance modality in use (25), treatment site (26),
patient positioning device (27), and other human errors. In recent years, researchers
have reported both systematic and random errors that are measured using kVradiograph using onboard imaging system and kV cone-beam CT (kV-CBCT) (See
Table 1-3). Overall, the average systematic and random errors reported are roughly
2mm (27, 28, 29, 30).

Table 1-3 A summary of systematic and random setup errors reported in recent studies.
Because not every author uses the same terminology to report patient setup errors, some
results in this table were re-interpreted or estimated from the original studies. Overall,
the average systematic and random errors are roughly 2mm.
Authors
Site
Huang et al. (28)
Prostate
Letourneau et al.(29)
Prostate
Arjomandyet al.(30)
Lung
Li et al. (27)
Lung
Average

Modality
kV-CBCT
kV-CBCT
kV-radiograph
kV-CBCT

Systematic (σ)
2.2mm
1.0mm
2.7mm
1.4mm
1.8mm

Random (Σ)
1.5mm
2.4mm
2.5mm
1.5mm
2.0mm

Although the magnitude of setup error is not necessarily larger for proton therapy than
the conventional photon therapy (i.e. assuming identical beam delivery process) the
impact of setup error on delivered dose distribution for proton therapy can be more
deteriorating. In order to estimate the effect of setup errors on the cumulative proton
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dose to a lung motion, Engelsmanet al. demonstrated the perturbation of dose
distribution due to the change in position of target volume (i.e. soft tissue) surrounded
by lung tissue (See figure 1-6) (31). In this study it was clearly demonstrated that the
conventional PTV does not guarantee target coverage for proton therapy.

Figure 1-6 When there is no setup error, the planned proton dose shows
good conformity to the target volume. However, when 10mm setup error is
introduced by shifting the target volume perpendicular to the incoming
beam direction, a significant under dosage and over-shoot of dose
distribution occurs along the beam direction (This figure is courtesy of
MartijinEngelsman from Holland PTC).
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In general, patient anatomy is a complicated mixture of different tissue types
and different lines of beam paths inside the patient can have significantly different
tissue densities. When a setup error occurs, a line of beam path whose proton range was
pre-calculated is no longer correct which can cause further range error in addition to the
inherent range uncertainty. In other words, for proton therapy, setup error is coupled to
range error. A misalignment of target volume in the direction perpendicular to the beam
path not only causes a partial geometric miss, but it can further cause over or undershoot of the proton beam in the direction parallel to the beam path.
A.3 Treatment planning and plan evaluation methods in proton therapy
In this section we briefly introduce the current treatment planning and treatment plan
evaluation methods with emphasis on how range and setup uncertainties are handled.
Passively scattered beam proton therapy treatment planning is significantly different
from treatment planning using photon external beam radiotherapy. One of the most
important differences is in the role of the planning target volume (PTV). International
Commission on Radiation Units and Measurements (ICRU) report No. 83 defines a set
of geometrical volumes that can be used during treatment planning procedures and these
conventions are well adopted in the conventional photon external beam therapy
treatment planning practice (32). In this convention, the gross tumor volume (GTV)
defines tumor volume that is visually evident from imaging (such as CT or PET). The
clinical target volume (CTV) is the tumor volume defined by the GTV plus a subvolume that includes possible extent of the primary tumor volume or microscopic
spread of diseases. The planning target volume (PTV) is the volume that extends further
from the CTV to include geometrical uncertainties in the CTV position. If time resolved
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4DCT is available, the extent of internal motion of the CTV through different breathing
phase can be combined to give the internal target volume (ITV) which is then expanded
further to the PTV (See figure 1-7).

Figure 1-7 Schematic of geometrical target volume expansions from GTV
(gross tumor volume) to CTV (clinical target volume) to ITV (internal target
volume) to PTV (planning target volume) according to the ICRU definition.

It should be noted that while the determination of GTV, CTV, and ITV are primarily
clinical in nature, the PTV is concerned more with the physical process of beam
delivery and its uncertainties. In other words, the PTV should be created differently for
different beam delivery methods and choice of therapy type. Previously, researchers
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have shown that the concept of PTV alone cannot ensure target coverage sufficiently for
proton therapy as it did for the conventional photon therapy (31, 33). The conventional
PTV is purely a geometrical concept and it does not account for the change in tissue
density due to setup or internal motion error in heterogeneous medium. In other words,
unlike dose distributions found in conventional photon therapy, proton dose
distributions can be perturbed as a result of both setup and internal motion error. For
this reason, the proton therapy community has instead developed treatment planning
methods for passively scattered proton therapy that focus on delivering dose to CTV
itself (rather than PTV) and deal with uncertainties through the design of beam-specific
hardware such as apertures and compensators. The aperture is a block that is cut-out to
have a shape of CTV in beam’s eye view in order to completely block the dose to
normal tissue outside of CTV laterally. The compensator is a block made out of Lucite
(or other material type with density similar to that of water) with variable thickness to
match the proton beam’s range to the distal surface of CTV (See figure 1-8).

Figure 1-8 An aperture (left) and a compensator (right).

18

In order to account for the geometrical miss of a target volume due to setup or internal
motion of a target, the aperture block can be cut-out further to extent the isodose line
laterally from the CTV. The inherent range uncertainty is accounted for by adding extra
depth in protons range during compensator design (i.e. to add margins distally, the
compensator thickness is lessened to increase proton range in patient). Furthermore, in
order to account for the range error caused by the change in local tissue density
distribution, the thickness of compensator is lessened further by the process called
“compensator smearing” (34). A compensator that is appropriately smeared can account
for the change in the WET along the beam path due to setup and internal motion error,
thereby maintaining sufficient dose coverage.
Despite its effectiveness in dealing with both setup and range uncertainties, there
are two major problems with this current method. First, this method cannot be used for
proton therapy using scanning beam delivery because scanning beam delivery does not
require apertures or compensators. The lateral spread of dose distribution is achieved by
steering a small pencil beam using steering magnets so it typically does not require an
aperture. Also, for scanning beam delivery method, the compensator is not required as
the range proton is controlled at the level of accelerator by changing its initial kinetic
energy. Second, in the absences of the PTV it is harder to evaluate the CTV coverage
under uncertainties. Another important role of the PTV in conventional photon therapy
is that it acts as a surrogate volume of CTV under the worst-case scenario: the PTV
coverage is related to the CTV coverage under assumed geometrical error. For this
reason, typically, a dose is prescribed and reported using the PTV instead of the CTV
itself. Despite these known limitations of the PTV in proton therapy, it is still used to
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prescribe and report dose in proton therapy treatment plans as there are no readily
available alternatives. Therefore, in this study, we propose to adapt the conventional
PTV to fit better with proton therapy in terms target coverage and also suggest different
uncertainty analysis method to evaluate CTV coverage under treatment uncertainties.
B. Objectives
The main objective of this research is to develop methods and tools to account
for the setup and range uncertainties in proton therapy that can apply to both passively
scattered and scanning beam delivery. First, we need to develop a treatment planning
method that ensures prescription dose is delivered to a target volume. Second, we need
a method to evaluate if a given treatment plan is indeed delivering the intended
prescription dose to a target as well as if dose limits for organs at risk are satisfied under
the influence of uncertainties.
B.1. Treatment plan designing method adapted to proton therapy
In this research we propose to modify the conventional PTV used in external
beam photon therapy to better account for the uncertainties related to proton therapy.
This will be achieved by considering beam by beam, ray by ray margin specific PTV or
beam-specific PTV.
B.2. Treatment plan evaluation method adapted to proton therapy
In this research we propose to add uncertainty analysis into the conventional
treatment planning assessment parameters such as dose objectives and dose-volume
histograms. This will be achieved by comprehensive statistical sampling methods to
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quantify both expectation value and standard deviation of interested dose related
parameters.
C. Hypotheses
We propose the following hypotheses in this research:
Hypothesis 1: A plan designed with a Beam-specific planning target volume
(bsPTV) can minimize the loss of target coverage due to setup and range
uncertainties when compared to a plan treated to a conventional planning target
volume (PTV).
Hypothesis 2: Statistical method can be used to quantify the variation in dose
distribution and dose-volume histograms (DVHs) due to setup and range
uncertainties.
D. Specific Aims
In order to resolve technical difficulties in testing our hypotheses, we propose following
specific aims.
Specific Aim 1: Develop and validate the concept of bsPTV and its ability to
maintain target coverage under setup and range uncertainties.
Specific Aim 2: Develop a robust plan analysis tool using statistical parameters and
quantify the effect of setup and range uncertainties on proton plans.
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CHAPTER 2: BEAM-SPECIFIC PLANNING TARGET VOLUME
Chapter2 is based on the material that was published in the International Journal of
Radiation Oncology and Biology and Physics in Feb, 2012 by the author of this
dissertation. [Int. J. Radiat. Oncol. Biol. Phys. 2012:82(2):e329-336. Written
permission has been obtained from the publisher for use of these materials in this
dissertation.

A. Introduction
As discussed in chapter 1, the greatest challenge in proton therapy treatment
planning is accounting for various uncertainties associated with actual dose
delivery, such as patient setup uncertainty, organ motion and proton beam range
calculation. For external beam radiotherapy using high-energy photon, some of
these issues can be addressed by using geometrical concepts, such as the
planning target volume (PTV) as introduced in the International Commission on
Radiation Units and Measurements reports (36, 37, 38). In general, the PTV is
created by adding geometric margins to the clinical target volume (CTV). The
CTV to PTV margins are determined by considering uncertainties that arise
during the treatment beam delivery process. The magnitude of errors resulting
from hardware performance uncertainties, patient setup errors, and internal
organ motion and external patient motion is specific to the type of radiation
being used. Therefore, unlike the CTV, the PTV should be treatmentmodality
and beam delivery method dependent. For example, size of the PTV can be
significantly minimized under the guidance of image-guided or adoptive replanning strategy whereas the CTV does not depends on the actual beam
delivery process. For external-beam photon treatments, it is assumed that the
spatial dose distribution from the photon plan may not be noticeably affected by
the geometric change in the target or patient’s anatomy (39, 40). Cho et al (41)
conducted a study showing that, for the majority of clinical cases, change in
photon dose distribution due to a small misplacement error of the target is
negligible and that simple uniform expansions of the CTV are adequate. The
fact that the dose distribution given by photons is insensitive to small
perturbation in CT density gave a rise to the term dose cloud. However, studies
of treatment margins for proton therapy have found that simple geometric
expansions of the CTV are inadequate for proton therapy treatment planning (42,
43). The difficulty of applying a geometric concept of the PTV to proton
therapy is due to the fact that proton dose distribution can vary substantially
when patient’s anatomy in the beam path is changed. In particular, misalignment
of the proton beam with the patient can cause significant cold spots or hot spots
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within the target volume in the presence of tissue heterogeneities, such as air
pockets, dense bone, or skin surface irregularities, near the beam path. We have
described this type of error that is unique to proton therapy as setup or internal
motion error being coupled to range error (i.e. it should be noted that setup error
induced range error is different from inherent range error discussed in chapter 1).
Due to setup error, these tissue heterogeneities may move into the beam path,
causing cold spots or hot spots. When using a simple geometric expansion of
the CTV,unanticipated changes in proton range can result in insufficient dose
coverage to the target (43-45). The magnitude of error that can be caused by
tissue heterogeneities misalignment is expected to be greater for treatment sites
with dramatic change in tissue density such as in lung and soft tissue boundary
(See figure 2-1).

Figure 2-1 Dose distribution re-calculated on inhale (right column) and
exhale (left column) is compared for Proton (top row) and IMRT (bottom
row).The arrow shows the boundary between liver and lung where dose
distribution changes significantly for proton while remains roughly the same
for IMRT. (Courtesy of Lei Dong Ph.D. Scripps Health)
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Moyers et al. (42) proposed abandoning the PTV concept and suggested
corrections be made by adjusting the beam-specific hardware, such as the
aperture and range compensator, in passively scattered proton treatments.
However, a scanning beam system can steer a small proton pencil beam to paint
large target while controlling the proton range directly by adjusting the initial
kinetic energy of protons extracted from accelerator, therefore, proton therapy
delivered using a scanning beam system does not use hardware beam shaping
devices. Therefore, most treatment planners using scanning beam proton therapy
use a conventionally derived geometric PTV concept to define the treatment
target (46, 47, 48, 49,50), which may not be ideal.
In this chapter, we investigate a PTV design method for proton treatment
planning using single-field optimization (SFO) via a beam-specific PTV
(bsPTV). The bsPTV concept will also apply for both passively scattered proton
plans and scanning beam proton plans, especially in the evaluation of such plans
to confirm adequate compensator designs. This method provides a significant
advantage over the conventional method using a single PTV for all beams
because the magnitude of each margin can be individualized for each field. For
passively scattered beam delivery method, the uncertainty caused by tissue
misalignment can be compensated by the compensator smearing technique as
proposed by Urieet al. (52). We will demonstrate a similar concept can be used
for constructing the bsPTV without a physical compensator. One unique
contribution in our implementation is that we converted the margin calculated
using the water equivalent thickness (WET) into a local distance (i.e. physical
distance in space) based on local density near the target region, which proves
important for evaluating target coverage in heterogeneous tissues, such as lung
or head & neck cancers.
B. Methods
B.1. Design of bsPTV
Our proposed method of designing a bsPTV, we primarily focused on
three types of uncertainties. First, a “geometrical miss” of the CTV due to
lateral setup error was accounted for by a lateral (in beam’s eye view) expansion
of the CTV. Second, inherent range uncertainties due to uncertainties in relative
stopping power ratio (89:) were accounted for by adding distal margins (DMs)
and proximal margins (PMs) for each ray trace from the beam source to the
distal and proximal surfaces of the CTV. Third, range error due to misaligned
tissue heterogeneity was accounted for by adding extra margins from a density
correction kernel that mimics the function of compensator smearing.
B.1.1 Lateral margin calculation
Foremost, it is important to cover the extent of target motion
geometrically as position of spots (i.e. where monitor unit of from a pencil beam
is defined) must be assigned to account for a “geometrical miss” of the CTV due
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to setup and internal target motion error. For this reason, the first step in creating
bsPTV is to expand the CTV laterally from the beam’s eye view using margins
that encompassed the typical setup error margin (SM) and internal motion
margin (IM). This step is similar to the aperture expansion step used in
passively scattered proton therapy treatment planning in the sense that the
margins are expanded laterally away from the beam axis rather than the patient
axes. Thus, lateral margins (LM) can be defined as
LM = IM CTV + SM

(1).

The magnitude of IM can be determined for each patient using four-dimensional
CT (4DCT). The magnitude of SM depends on the confidence level based on
experience of therapist, institutional history, immobilization, and imageguidance procedure.
B.1.2 Distal and proximal margin calculation
The second step in designing the bsPTV was to account for the range
error; the combination of errors resulting from the uncertainties in the
calibration curve used to convert the computed tomography (CT)number (in
Hounsfield units [HU]) to the proton stopping power and from the uncertainties
in the HU values themselves that may appear during CT acquisition (i.e., due to
artifacts in the CT images). Accurate estimation of range uncertainty due to CT
HU to stopping power conversion still remains a challenge (53-55). In this study,
we used 3.5% of the WET to the target as the range error,following the current
protocol used at our institution for passively scattered treatment field design. In
order to account for range calculation error more precisely,the magnitude of the
DMs was specific to each ray directed through the target volume (i.e. the
laterally expanded CTV). First, we computed a “range matrix” whose pixel
value representedtheWET of protons in a 1x1 x 2.5 mm grid (i.e. or equivalent
to the CT grid space) perpendicular to the beam direction. For example, the
relative radiological path lengths for distal ( Di , j ) and proximal ( Pi , j ) rays
representing the index (i, j ) of the range matrix were calculated by integrating
the line segments sc and sb as follows (see figure 2-2):
c

Di , j = ∫ rsp (i , j , z ) dz

(2)

s
b

Pi , j = ∫ rsp (i , j , z ) dz

(3)

s

where rsp (i, j , z ) is the relative stopping power ratio function of the given CT
data; that is, each CT number along the line segment is converted to its
corresponding relative stopping power ratio from the previously measured
calibration curve (56). Both the DM i , j and PM i , j for a given ray were found by
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taking 3.5% of the radiological path length that was calculated usingEqs. (2) and
(3).
DM i , j = Di , j × 3.5%
PM i , j = Pi , j × 3.5%

(4)
(5)

All the rays and their corresponding PMs and DMs were calculated accordingly.
All margins were measured in WET.This step is illustrated in figure 2-3 (c).

Figure 2-2A schematic illustration of the method used to calculate the range
matrix and relevant margin of a ray. Radiological path length is calculated
per ray, and a kernel is applied to replace the radiological path length of a
given ray with the local maximum within a distance (the lateral setup error
and organ motion) of the range matrix. 3.5% of the assigned path length is
used to convert to physical depth to form a margin (distal cd , proximal ab ).
[Permission to publish this figure was obtained from the Int J OncolBiolPhys]
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Figure 2-3 An illustration of the four essential steps in creating the bsPTV (red
contour) from a CTV (green contour)with a dense object (grey sphere) along the
beam path. (a) The CTV is expanded laterally away from the beam axis using
the expectedmotion margin (IM) and setup margin (SM). (b) From a given
beam angle, ray tracing is performed to calculate the radiological path length of
each ray from the source to the both distal and proximal surface of the laterally
expanded CTV (blue contour). (c) The fraction of the total radiological range
calculated in previous step is used to the distal margins per ray. (d) Correction
for interplay effect of setup and range error is accounted by applying the
correction kernel and the radiological path length margins are converted to
physical depth margins. [Permission to publish this figure was obtained from
the Int J OncolBiolPhys]

B.1.3 Correction for tissue density misalignment
So far margins treated in this method concerns only with setup and range
error independently. However, it is clear, that the setup error is coupled to a
further range error as they are bounded by the line integral in Eq. (2 and 3). This
type of error is described as the misalignment of tissue heterogeneity as it only
occurs in inhomogeneous medium. In order to account for the misalignment of
tissue heterogeneity, we replaced Di , j for a given ray with the WET ( DMax ( i , j ) )
found within a distance defined by the lateral setup error and organ motion
perpendicular to the ray line: this is done by applying local maximum filter
kernel in the range matrix that was pre-calculated. This maximum WET is then
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used to compute DM i , j . Similarly, the same operation was applied to proximal
side by replacing Pi , j with the minimum (rather than the maximum)
WET( DMin ( i , j ) ). This process was repeated for all rays. This process is
conceptually equivalent to the physical range compensator smearing technique.
B.1.4 Conversion to physical depth margin
The margins calculated above are defined in terms of the WET.
However, surrounding tissues of CTV where bsPTV is expanded may be
heterogeneous with different density. In such case, the margin based on WET
calculation must be re-converted back to the physical distance according to the
local density in order to visualize bsPTV and overlay onto the image of patient
and compare the isodose lines with PTV volume directly. Therefore, in the final
step, we converted the water-equivalent bsPTV to a physical bsPTV with
identical radiological path length using the local density information from the
CT data. Thus, we expressed the resulting physical depth margins of a given ray
line as follow:

DM iPhysical
= d −c
,j

(6)

PM iPhysical
=b−a
,j

(7)

where the points c and d (a and b for proximal) are the limits of the following
integral:
d

DMax ( i , j ) × 3.5% = ∫ rsp (i, j , z )dz

(8)

c
b

PMin ( i , j ) × 3.5% = − ∫ rsp (i , j , z ) dz

(9)

a

Figure 2-3 shows a step-by-step illustration of bsPTV formation using the
method described here.
B.1.5 Software Implementation
Because existing treatment planning system could not produce the
bsPTV, we implemented the calculation in standalone software written in
Matlab (Mathworks, Natick, MA). The software takes DICOM CT images,
structure set, and RT plan as input. The software allows the selections of a target
(CTV), a beam angle, and various parameters related to setup errors and range
uncertainties. The software will calculate and create the bsPTV as a DICOM RT
structure contour, which can be imported back to the treatment planning system
(See figure 2-4).
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Figure 2-4 Final implementation of bsPTV software. It takes DICOM images
and structure file of patient, expected setup and internal motion margin, and
range uncertainties, and selected beam angle, in order to compute beam-specific
planning target volume that can be exported as another DICOM structure file.
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B.1.6 Validation Study
In order to validate the design method and its software implementation
we designed an experiment based on a phantom.A virtual CT phantom with a
water-equivalent body, a CTV, and a high-density object was created. The CTV
(50 Hounsfield unit [HU]; volume = 50.4 cm3 ) was placed at the center of the
body of water-equivalent material (0 Hounsfield unit [HU]), and the highdensity object (1800 HU; volume = 1.9 cm3 ) was placed approximately 5cm
upstream of the proximal surface of the CTV in order to create heterogeneity
that can contribute as a source of added range uncertainty in case of
misalignment. The conventional PTV was constructed in order to compare the
results with bsPTV. The PTV was derived by expandingtheCTV as follow: 8mm margin was used to expand the CTV laterally in the beam’s eye view to
create the PTV. The 8-mm LM was carefully selected to make sure the
magnitude of simulated setup error (i.e. 6 mm) does not exceed this bound.For
the sake of simplicity, we wanted to make sure that in case under dosage to CTV
occur during our simulation, it should occur at the distal and proximal surface of
the target volume rather than from lateral geometrical “hit or miss”. DM and
PMvaluesof8.5mm and 7.5mm, respectively, were calculated using the
following equations:
DM = 3.5% × ( distal CTV depth) + 3mm

(10)

PM = 3.5% × ( proximal CTV depth) + 3mm

(11)

The extra 3mm margins from the above equations are used to account for
inaccuracies in dose calculation algorithm to handle large angle scatter and
nuclear interactions in the proton beam as well as the inaccuracy in
manufacturing compensators. It should be noted that for scanning beam proton
therapy where compensator and aperture that adds uncertainty in our ability to
calculate range is missing, the addition of 3mm can be lessened or completely
ignored. Similarly, for the bsPTV, the same 8-mm LM was used to expand the
CTV. The method described in the previous section was used to expand the
CTV in the distal and proximal directions with a uniform setup error of 6mm,
which resulted in a non-uniform expansion of the CTV for both the distal and
proximal surfaces. It should be noted that in creating PTV and bsPTV, there is
not lateral margin bias but difference is in proximal and distal margin.
A treatment plan using a single field with a gantry angle of 270°
(directed from the patient’s right to his/her left) that passed through the highdensity object was created using SFUD to give a uniform dose of 200cGy to the
PTV and likewise to the bsPTV. Other than the primary target volume, all other
treatment planning parameters were the same for both PTV and bsPTV plans.
To compare the robustness of the plans based on the PTV and bsPTV, we
applied the original treatment beam data to CT data sets under different
combinations of errors and recalculated doses for each simulation. Setup error
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was simulated by shifting the entire CT data set from its original isocenter from
0mm to 6mm in increments of 2mm perpendicular to the beam axis. Internal
motion was simulated by moving the high-density object from 0mm to 8mm in
increments of 2mm with respect to the center of the CTV along the same
direction of the body shift. Systematic proton range error was introduced into
the simulation by increasing the HU values of the entire CT data set by 3%
which is close to 2.1% of radiological range error in the soft tissue region (i.e.
this is according to the CT to stopping power ration calibration curve we used).
Different combinations of setup, motion, and range errors resulted in 40 unique
dose distributions for each plan using the PTV and bsPTV.
C. Result
The resultant bsPTV closely conformed to the PTV except for the area where
the smearing operation had the greatest impact. The final bsPTV was slightly
larger than the PTV owing to the “horn-like” expansion asshownin figure 2-3 (d).
The measured volume of PTV and bsPTV were 126 cm3 and 161 cm3 ,
respectively. Figure 2-5 shows examples of the dose distributions for some of
the conditions used in the PTV and bsPTV treatment plan comparisons.

Figure 2-5 Dose distributions when conforming dose to the CTV (inner circular
contour) using plans based on the PTV and bsPTV. From outside to inside, the
isodose lines of 90% (blue), 85% and 80% (red), and 70% (orange) are shown.
[Permission to publish this figure was obtained from the Int J OncolBiolPhys]
The left column shows the dose distribution of plans designed using the PTV,
and the right column shows the bsPTV as described in the previous section. The
top figures show the dose distribution under normal conditions and no setup or
motion uncertainties, while the bottom figures show the dose distribution with
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CT data with 3% increase in the CT number and a 6-mm setup error and an
8mm shift of the high-density object. As one expects, when there is no
introduced error, both plans dose distribution conforms well to the CTV and no
cold spot within the CTV is observed.
The minimum percent dose which is the minimum dose found within the
ROI as a percentage of the prescribed dose was used to measure the
performance of both PTV and bsPTV. For the plans using the PTV as the
primary target, with the normal CT data set, the minimum percent dose coverage
to the CTV dropped from 99% to 95% with a 6-mm setup error, to 94% with
an8-mm motion, and to 88% when both setup error and motion were applied
(see Figure 2-6 a). The modest drop in PTV coverage here is from the margins
calculated for both the proximal and distal edges using Eqs. (10) and (11) were
meant to account for the systematic range calculation error. To take this
systematic range calculation error into consideration in conjunction with both
setup error and motion, we increased the CT number by 3% of its original value
and recalculated dose distributions using the original beam data. Using this
range uncertainty imbedded CT set, the minimum percent dose coverage to the
CTV dropped from 99% to 92% with a 6-mm setup error, to 83% with an 8-mm
motion, and to 67% when both setup error and motion were applied (see Figure
2-6 b). Despite using PTV margins that exceeded the simulated uncertainties,
dose coverage to the CTV was not maintained owing to the misplacedhighdensity object. Most of the underdosage occurred at the distal surface of the
CTV along the lines passing through the high-density object.
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Figure 2-6 The minimum percentage ofprescribeddoseto the CTV for (a) plans
using PTV simulated with original CT data, (b) plans using PTV with 3% upscaled CT data, (c) plans using the bsPTV with original CT data, and (d) plans
using bsPTV with 3% up-scaled CT data. The lines represent different setup
errors ranging from 0mm to 6mm while the horizontal axis represents increasing
motion errors of the dense object from 0mm to 8mm. [Permission to publish
this figure was obtained from the Int J OncolBiolPhys]
The right-hand images infigure 2-5 show the dose distributions for plans
that were designed using the bsPTV, which was derived from the CTV using an
8-mm LMplusPM and DM calculated as described above. For this plan, using
the normalCT data set, the minimum percent dose coverage to the CTV dropped
from 99% to 95% when both 6mm of setup error and 8mm of motion were
introduced. Unlike the plansusing the PTV, plans using the bsPTV showed little
change in the minimum dose coverage to the CTV when using the modified CT
data set. Under conditions of the largest simulated treatment uncertainty using
the modified CT data, the dose coverage of the CTV dropped to 94% (see figure
2-6d). The range calculation error introduced by scaling up the CT numbers by
3% did not affect the dose coverage to the CTV when using the bsPTV as the
primary target volume.
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D. Discussion
In this chapter we developed and showed our implantation of the beam-specific
PTV concept in order to account for the setup and range uncertainties in proton
therapy. The results of the simulation study support the appropriateness of using
bsPTV to calculate adequate margins to guarantee dose to CTV coverage for
charged particle therapy. Previous studies have shown thatthe magnitude of
required target margins depends on the beam’s direction in proton therapy(50,
57) but specific designing methods to create such bsPTV have not
beenpublished in open literature. Thus, this study fills an important gap in the
goal of creating robust and yet practical target volumes particularly for scanning
beam proton therapy system that relies on the conventional PTV method
currently. The fundamental difference between the bsPTV design we have
describedin this paper and the conventional PTV is that the bsPTV method
createsDMs and PMsthatare varied along different rays according to their
radiological path lengths. Furthermore, the bsPTV adds extra margins to
account for possible range errors due to the misalignments of heterogeneous
tissues traditionally done by compensator smearing. In addition, the final
bsPTV takes into account local density variations of anatomical objects in the
patient. The final shape of bsPTV is not intuitive in as it depends on the local
density heterogeneity. In figure 2-7 we demonstrated the beam angle dependent
characteristics of bsPTVs for one prostate and one thoracic case.
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Figure 2-7 The CTV (green contour) is used to derive two bsPTVs (red and blue
contours) under same specification (setup and range error) at different angles.
(a) For prostate site, both bsPTV shows characteristic horn like distal shape to
account for the misalignment of highly dense femur and femoral head. (b) For
thoracic site, the two bsPTVs are significantly different in its shape and volume
due to the difference in tissue density along their beam paths. [Permission to
publish this figure was obtained from the Int J OncolBiolPhys]
It is evident that the bsPTVs look different for different beam angle. In fact, in
certain case the sheer size of the bsPTV can be obviously bigger than the other
beam angle that it can help avoid beam angle that requires large margins in order
to spare dose to normal tissue. However,forahomogeneous medium, the bsPTV
should be similar to that of the conventional PTV, provided the PTV expansion
is along the beam direction. In general, the size of the bsPTV will increase with
increasing radiological path length to the target, setup error and the range of
organ motion.
Although the focus of this study was the utility of bsPTV as a robust
proton planning tool, it is worth mentioning that defining the bsPTV may also be
useful in plan evaluation. In conventional photon therapy, the dose-volume
histogram (DVH) of the PTV is compared to the DVH of the CTV in order to
judge the robustness of a given plan. In a way, the PTV coverage is a surrogate
of the CTV coverage under uncertainty. This comparison assumes the PTV is
large enough to contain the CTV of uncertain position during the course of
treatments. Therefore, the DVH of the PTV is typically seen as the worst-case
representation of CTV coverage in photon therapy. In proton therapy, however,
such an interpretation of the DVH of the PTV does not work wellbecause of the
sensitivity of proton dose distribution to tissue heterogeneity and setup error.
Currently there is no readily accepted method to evaluate a proton plan other
than performing multiple dose calculations withsimulated isocenter shifts. In
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figure 2-8, the DVH of the PTV and the DVH of the bsPTV under original
conditions from our phantom study are shown separately along with all the
DVHs of the CTV under the different simulation conditions.

Figure 2-8. The DVHs of the CTV (blue lines) under simulated setup
error and motion. (a) Plan using PTV, also shown here is DVH of PTV
(red dotted line). (b) Plan using bsPTV, also shown here is DVH of
bsPTV itself (red dotted line). [Permission to publish this figure was
obtained from the Int J OncolBiolPhys]
The arrow on figure 2-8 points to the area where some of the DVH curves
reflect much worse coverage of the CTV than of the PTV itself, indicating that
the DVH of the PTV does not necessarily represent the worse-case scenario for
CTV coverage despite the fact that the PTV is derived by adding margins to the
CTV that exceed the simulated geometrical uncertainty. In contrast, the DVH of
the bsPTV curve conforms closely to the DVH curves of the CTV in this area,
indicating that the coverage to the bsPTV closely represents the worst-case
coverage for the CTV. Thus, it should be possible to use the difference in
coveragebetween the bsPTV and CTV as a heuristic technique for evaluating the
robustness of the proton treatment plan.
The fundamental assumption used to derive the method of generating the
bsPTV is that a uniformhomogeneous dose is delivered to the volume being
defined. When multiple beams are used and each beam is used to deliver
uniform dose to the target, the bsPTV should be evaluated for each individual
beam. It will be difficult to assess the overall target coverage because the interrelationship of different bsPTVs is difficult to combine into one PTV. The
method presented in this paper will not be applicable to multi-beam,
simultaneously optimized proton plan, such as the intensity- and energymodulated proton therapy (IMPT) (58).
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E. Conclusion
In this chapter, we investigated a practical method to create beamspecific PTV (bsPTV) for treatment planning and evaluation of proton beams. In
current practice, scanning beam proton therapy using single-field optimization
lacks a well-defined way of dealing with treatment uncertainties. The bsPTV
takes into account both setup errors and range calculation uncertainties for the
specific beam angle. The bsPTV can be used to directly design and evaluate a
proton treatment plan similar to the geometric PTV concept used in the photon
treatment planning. We demonstratedthatthe conventional (geometry-based)
PTV concept in photon therapy failed to guarantee the prescribed dose coverage
of the target in proton therapy because the dose distribution of protons is
influenced by tissue heterogeneity along the beam’s path. We demonstrated that
the proton plan designed based on bsPTV concept provided better target
coveragein the presence of setup error and range uncertainties.

F. Appendix
In this chapter we described the method of generating beam-specific PTV (bsPTV) that
is robust against setup uncertainty, internal target motion, and range error of proton
beam. However, the discussion regarding the determination of input parameters needed
to generate bsPTV was omitted. In this appendix, we will briefly discuss how bsPTV
margin parameters can be determined in clinical practice. In our validation study, we
designed PTV and bsPTV using same lateral margins (i.e. 8mm). The rational of
choosing 8mm lateral margin comes from the design of our validation study: we
intended to simulate setup and internal motion error up to 8mm therefore having that
8mm lateral margin would provide just enough coverage on the lateral region of our
target volume. For the purpose of our validation study, the 8mm margin was an
arbitrary choice (i.e. we could have easily shown the similar result with different
margins)and its choice wasn’t important as long as the same lateral margin is applied to
both PTV and bsPTV to create fair comparison.
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In clinical practice, the determination of margins or the parameters that are needed to
generate bsPTV would be of a significant importance. For PTV, margins are typically
derived by considering all the geometric uncertainties (i.e. setup error, organ motion,
and target delineation). According to the ICRU report No 78, the systematic and
random portion of such errors can be added in quadrature to derive overall margin as
follow.
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Once the above overall systematic and random errors are determined, one can follow a
model based margin determination formalism to determine the magnitude of
geometrical margin sizes. In general, the sizes of such margin will depend on the
desired target coverage in certain proportion of population.For example, Stroomet al(39)
suggested that to ensure at least 95 percent of the dose is delivered to 99 percent of the
CTV in 95% of patient population, one needs to derive margin by summing systematic
and random error with following weights:
h7i  j7i $^8kl  2Σ Z 0.7σ

(14)

In this formalism, the systematic error is weighted twice more heavily than the random
error. Van Herket al(59) and McKenzieet al(60) formulated similar margin recipe for
different clinical sites. The method of determining these weights go beyond the scope of
our discussion but it should be noted that the precise determination of such weights are
difficult as they are dependent on patient setup procedure, tumor location, and beam
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penumbra. Although these margin recipes provide ways to determine PTV margins
without ambiguity, in most clinical practice, the margins are defined based on the
experience and confidence of clinical staffs involving patient setup and treatment
planning.
For bsPTV, lateral expansion (i.e. respect to beam’s eye view) of original CTV volume
can be considered identical to the expansion in the conventional PTV. In terms of lateral
coverage, there’s no conceptual difference between the conventional PTV and bsPTV
since the purpose of lateral margin is to cover the geometrical misplacement of CTV
volume with respect to beam’s eye view. However, for bsPTV, both proximal and distal
margins are determined uniquely for different field direction for different patient.
Furthermore, the magnitude of required margins is not geometric and must be
determined through ray-tracing of patient body along the beam direction. For these
reasons, in bsPTV creation, both proximal and distal margins are determined not by
population based generic formula as was done for PTV using equation (14). Therefore,
to describe bsPTV margins in terms of the objective of covering certain percentage of
patient population is not suitable. In our implementation of bsPTV software, we let user
input both the magnitude of setup error and internal motion error as well as the expected
range uncertainty.

Based on these numbers, and by incorporating the ray-tracing

algorithm and conversion of water-equivalent thickness (WET) to the physical distance,
proximal and distal margins are determined. The magnitude of setup error and internal
motion error should be determined based on the clinical experience and confidence in
patient setup and simulation procedure. For example, if treatment planning incorporates
4DCT to acquire internal target volume (ITV), the internal motion error can be set to
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zero. The range error is specified as the percentage of the total WET from the skin to
the distal surface of the target volume. Currently, based on the study performed by
Yang et al(20) and Moyer et al(22), this number is estimated approximately 3-3.5% two
standard deviations.
In summary, in creating bsPTV, its lateral margin should be determined similar to the
way PTV lateral margin is determined. However, for both proximal and distal margins,
a geometric and population based generic formalism should not be used, instead, the
margins should be determined for each patient for each selected beam angle.
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CHAPTER 3: Application of Beam-Specific PTV in Beam Angle Optimization
A. Introduction
In chapter 2, we developed and implemented the beam-specific planning target volume
(bsPTV) for creating a proton therapy plan with built-in robustness in target coverage
under setup and range uncertainties. In this chapter we show another application of
bsPTV: bsPTV as an objective function in beam angle optimization for lung cancer
proton therapy. In the discussion of chapter 1, we briefly discussed that the size and
shape of bsPTV is different for different beam angle selected, in some cases it can be
used as an evaluation tool of a selected beam angle simply by visually assessing the size
and shape of the bsPTV (61). The beam angle optimization problem is unresolved
problem that is currently under extensive investigation and research for both photon and
proton therapy (62, 63, 64, 65). Beam angle selection is one of the most important
decision making steps in radiotherapy treatment planning. Once a beam angle is
selected, a treatment field is tailored respect to the beam angle to shape a dose
distribution to meet overall plan objectives. The magnitude of which the selected beam
angle effects the overall dose distribution is inversely proportional to the total number
of beam angles used. As there are more treatment fields, the weight of monitor unit
from each field is decreased. Therefore, it can be argued that for a typical lung cancer
case, beam angle selection is more important for proton therapy than the conventional
photon based intensity modulated radiation therapy (IMRT) since a number of fields
used for proton therapy is two to three times less than a number of fields used in IMRT
(i.e. typically, proton plan employs 2 to 3 fields while IMRT employs 5 to 9 fields (see
figure 3-1).
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Figure 3-1 An example of typical field arrangement for IMRT (left) and proton
therapy (right) of lung cancer. In IMRT, 5 to 9 fields are selected while for proton
therapy only 2 to 3 fields are typically required.

Furthermore, due to the physical characteristics of proton beam, overall plan quality is
much more sensitive to a given beam angle for proton than IMRT. As discussed in
chapter 1, when accounting for the inherent proton range uncertainty the conventional
3.5% water equivalent thickness (WET) of the radiological path length varies
significantly over the span of available beam angles. There are two factors contributing
to this. First, the depth of target is different for different beam angle. When we account
for the range error by taking 3.5% of the total depth in WET, the distal margins of a
beam angle with deeper depth would be necessarily larger than other beam angles
resulting increased dose to normal tissue surrounding the tumor volume. Furthermore,
when creating a spread-out Bragg peak (SOBP), both entrance dose and proximal dose
can change for different beam angles because for different angle both target depth and
the required width of SOBP is different. In general, entrance and proximal dose
increases as depth and width of SOBP increases. We showed the magnitude of such
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increases in figure 3-2 where the SOBP with varying depth and width were simulated
using an analytical functions of proton depth dose (66, 67).
In this simulation, we found that the entrance dose can rise about 30% of the dose in
plateau region of the SOBP when increasing the width of SOBP from 3cm to 5cm at
10cm depth. Secondly, another significant factor to be considered in beam angle
selection process is the local tissue density. Because the local tissue density near the
tumor volume can vary along the beam direction, when a calculated distal and proximal
margins in WET is converted back to a physical depth distance, the final margin can
change as much as in the order of three times when going from soft tissue (i.e. tumor) to
lung tissue (see figure 3-3).
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Figure 3-2 Proximal dose as a function of target depth (a) and varying
width of SOBP (b) simulated with analytical functions. The proximal
dose is larger for a beam angle with deeper target depth and larger width
of the SOBP.
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Figure 3-3 An example of bsPTV for the selected beam angle (red straight line).
Both blue and red bsPTV contours are shown in magnified view (right) that
were generated using constant 3.5% and 3.0% WET margins. Distal to the PTV,
the physically converted margin extends up to 3mm in soft tissue, where it
extends to 7 mm in lung tissue.

In general, when designing a treatment plan for proton therapy, different margins that
account for uncertainties in beam delivery process are added to each fields (i.e. lateral
aperture margin, distal and proximal margin, and compensator smearing margin). The
addition of these margins to the beam shaping devices usually enlarges irradiated
volume, ultimately increasing the dose to normal tissue surrounding the tumor volume.
It is difficult to visualize the effect of added margins on the final dose distribution
before a full dose calculation is performed. The iterative process of calculating dose and
modifying a beam angle configuration is a time consuming process. On the other hand,
in chapter 2, we pointed out that the bsPTV can be used as an evaluation target volume
because its contour represents the necessary area to be irradiated at the full prescription
dose level in order to achieve the desired target coverage under the assumed
uncertainties (see figure 3-4).
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Figure 3-4 A comparison between the bsPTV (left) and planned dose
distribution (right). The bsPTV mimics the isodose line of prescription dose
level very closely.
Our goal in this study was to optimize beam angle configuration of lung cancer proton
plan by using volume of bsPTV as an objective function to be minimized (i.e. inter- or
union of volumes of bsPTV). The rational for proposing to use the bsPTV as an
objective function are:
1. Beam angle that requires larger distal and proximal margin will have larger
volume of bsPTV and should be avoided.
2. Beam angle that requires larger depth and width of SOBP will have larger
volume of bsPTV and should be avoided.
3. Beam angle with beam passing through greater amount of tissue
heterogeneity will have larger volume of bsPTV and should be avoided.
It should be noted that fully applicable beam angle selection method should consider
other equally important objectives such as dose limit to the organs at risk (OAR) that
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cannot be directly assessed through the volume of bsPTV alone. Ultimately,
incorporating more objectives would require a full dose calculation for every
combination of beam angles that requires very expensive computing power that is not
readily available in clinics. A full development of such a tool for proton therapy is a
beyond the scope of this dissertation therefore, the purpose of this chapter is limited to
showing the feasibility of using bsPTV as one of the objective function to be optimized
when selecting beam angle for a lung cancer patient.
B. Method
A lung cancer patient who was recently treated using passively-scattered beam proton
therapy at our institution was randomly selected for this study. The patient was
prescribed receive 74Gy to the clinical target volume (CTV) with dose limiting
requirement to total lung i5p= q 37%; mean lung dose (MLD) q 22Gy; and as low as
achievable to esophagus iYrp= and irp= ; heart iY5p= and iW5p= ; and maximum spinal
cord dose q 50Gy. The two-field (i.e. two beam angles) plan was designed by a
certified dosimetric and approved for treatment by a certified physician. The treatment
plan information and patient CT image set and structure set was exported from
treatment planning system (TPS) as DICOM formatted files. These files were imported
to the bsPTV software (see chapter 2, figure 2-4). The bsPTV was created with setup
error parameter set to 5mm and internal motion error 0mm (i.e. the patient showed
insignificant breathing motion and the integrated growth tumor volume was painted
with constant CT Hounsfield number when calculating dose using average 4DCT in
order to compensate for the slight change in tissue density). The inherent range
uncertainty of 3% was incorporated into the bsPTV calculation. The smearing kernel
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with 5mm smearing distance was also applied to account for the misalignment of local
tissue heterogeneity. The volume bsPTV generated under these parameters were
recorded for angle spanning from 0 degrees to 360 degrees in 10 degrees interval.
Furthermore, the volume of overlap and the volume of intersection between two
bsPTVs for a pair of beam angles with every possible combination were computed and
displayed as 2D hot-map. The final two fields beam angle configuration was selected
based on the combination of beam angle pair that gave the minimum of linear sum of
the volume of overlap and the volume of intersection. A treatment plan with new beam
angle configuration was created in TPS with identical treatment planning parameters of
the original clinical plan. The dose distributions and dose-volume histograms (DVHs)
calculated from TPS for both plans were compared.
C. Results
Figure 3-5 shows the resulted bsPTVs for selected beam angles. A significant difference
in both shape and volume of bsPTVs for different beam angles are observed. In general,
the most significant factor contributing to the increase in volume of bsPTV was the
amount of lung tissue present in the distal end of the selected beam path. This was
because the relative stopping power ratio of the lung tissue was about 3 times less than
the relative stopping power ratio of the tumor tissue, resulting in increased physical
distal margin to account for the inherent range errors.
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Figure 3-5 bsPTVs (red contour) for different beam angles (red line)
computed to account for 5mm setup and 3% inherent range uncertainties.

The overall influence of each sources of uncertainty (i.e. setup and range uncertainty)
on the volume of bsPTVs can be seen in figure 3-6. Once can see from the figure 3-5
that the volume of bsPTV computed based on the range error alone is larger than the
volume of bsPTV computed based on the setup error alone, indicating that the range
uncertainty is contributing slightly larger to the overall treatment volumes. When only
one beam angle is considered, the optimum beam angle that has the lowest required
volume of bsPTV was found to be at 0 degrees or the anterior-posterior field.
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Figure 3-6 Figure of merit showing the variation of the volume of
bsPTV over the span of beam angles. The computed volumes of
bsPTVs vs. beam anlgle under the effect of setup error only (blue),
range error (red), and both combined (green) are shown here separately.

The volume of intersection and the volume of union of multiple a pair of bsPTVs of all
possible configurations (i.e. 630 pairs) were computed as shown in figure 3-7 and the
linear sum of the volume of union and intersection that was to be used as the one final
objective function to be minimized was represented in color map as shown in figure 3-8.

50

Figure 3-7 The volume of intersection (yellow) and the volume of union (blue) of two
bsPTVs are shown for a few selected beam angle configurations. The red colored region
represents the original CTV that is used to expand bsPTVs.

Our objective function leads us to find the optimum beam angle configuration of 110
and 130 degrees as supposed to 30 and 90 degrees used in clinical plan. Figure 3-9 and
figure 3-10 shows the dose distribution resulted from the plan with optimized beam
angles vs. clinical plan was compared visually and the DVHs of lung, esophagus, hear,
and integrated-clinical target volume (ICTV) respectively. Our results show a
significant reduction in lower dose region of lung. However, we also observed slight
increases in heart dose while both dose to esophagus and ICTV remained the same.

51

Figure 3-8The color map of values representing linear sum of the volume
intersection and the volume of union of a bsPTV pair. The optimum beam
angle configuration was found by search for the minimum (i.e. 110 and 130
degrees).
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Figure 3-9 A comparison of dose distribution of the clinical plan (left) and the beam
angle optimized plan (right).

Figure 3-10 The resulted DVHs of clinical plan (solid line) and
optimized plan (dash line)
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D. Discussion
The volume of bsPTV was most sensitive to the amount of lung tissue present in the
beam path. The WET margins accounting for both setup and range uncertainties in lung
tissue dramatically increased the physical depth dose requirement which in turn resulted
in irradiating a large portion of normal lung tissue both distal and proximal to the tumor
volume. As a result, when we optimized the beam angle configuration of the given plan
purely based on the minimum volume of bsPTV, we were able to lower dose to the lung
significantly as shown in figure 3-10. However, our optimization ignores other
dosimetric goals such as dose to the heart, esophagus, and etc. We observed an increase
in heart dose in the optimized plan. It can be expected that for lung cancer cases, beam
angle configuration optimized based on bsPTV volumes only, would minimize dose to
lung while dose to other organs at risks can either increase or decrease.
E. Conclusion
In this chapter we showed that the bsPTV developed in chapter 2 for the robust
planning of proton therapy can be used for the purpose of beam angle evaluation and
beam angle optimization by minimizing the volume of a bsPTV for a single field plan
or a combination of intersection and union volumes for multi-fields plan. The rational
for using bsPTV as the objective in beam angle optimization problem is based on the
fact that a large volume of bsPTV is required if the given beam angle is more vulnerable
to the uncertainties that were considered in creating the bsPTV (i.e. setup and range
uncertainties). By reducing the margin required to create bsPTV, we can reduce dose to
normal tissue as shown in this chapter for the selected patient case. However, a full
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optimization must involve dosimetric objectives that correctly reflect other equally
important dose limit criteria.
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CHAPTER 4: FAST PROTON DOSE APPROXIMATION FOR ROBUST PLAN
EVALUATION
Chapter4 is based on the material that was published in the Physics in Medicine and
Biology in Jun, 2012 by the author of this dissertation. [Phys. Med. Biol. 2012
57(11):3555-3569. Written permission has been obtained from the publisher for use of
these materials in this dissertation.]
A. Introduction
In this chapter we describe and show our validation of the fast proton dose
approximation method that will be used to develop out robust plan evaluation
tool in chapter 5. Understanding and inclusion of various effects of treatment
uncertainties during treatment planning procedure is of significant importance to
reach desired clinical outcome. Careful assessment of treatment uncertainties by
accounting those into a treatment plan design in terms of increases in treatment
margin or modification of beam shaping devices (e.g. aperture, compensator,
and etc.) is essential in creating a robust plan. A robust plan by definition is
robust in terms of its ability to deliver prescription dose to a target and to
maintain dose constraint to critical structures under uncertainties. The treatment
planning dose distribution is only a snapshot of the dose based on the assumed
setting at the time of calculation and is therefore subject to variations under
different conditions, including patient setup and anatomical changes. As was
discussed earlier in chapter 2 and 3, the difference in what was planned and
what was actually delivered to a patient due to such changes is expected to be
greater for proton therapy than the conventional photon therapy because proton
beam ranges depend heavily on the tissue density along its path. Any changes
that can influence the given water equivalent thickness (WET) of the proton
beam can potentially result in differences between the delivered and planned
dose distributions, thereby making proton plan inherently less robust than the
photon counterpart.
Uncertainties in setup and range error can cause differences between the
value of WET from the treatment plan and actual WET at the time of beam
delivery (68, 69, 70, 71). For example, respiratory motion can cause lung and
thoracic tissues and the tumor to move during treatment such that the WET
along the beam’s path can change in any given breathing cycle (72). Also, in
multi-fractionated radiotherapy, as tumor response to radiation, a significant
deformation or volume shrinkage as well as the patient weight loss can alter the
intended dose distribution (73). For the conventional external beam radiotherapy
using high-energy photon beam, geometrically expanded volume such as the
planning target volume (PTV) or planning organ-at-risk volume (PRV) are
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routinely used for robust treatment planning and evaluation (74, 75, 76). Under
the assumption that the dose distribution given by photon beam is static, if PTV
that encompasses the clinical target volume (CTV) is sufficiently covered by the
prescription dose, then as long as CTV resides within the volume bounded by
the PTV, we can expect that the coverage of CTV is guaranteed. In terms of
treatment evaluation, dose coverage to PTV and PRV acts as surrogate volume
of CTV and OAR to be evaluated under uncertainties. However, this is based on
the assumption that the dose distribution is not altered in anyway by the motion
of CTV or patient body. While this static dose assumption is fairly accurate for
photon beam (77) it is not true for proton beam (78, 79).
Ideally, in order to gauge the robustness of a given proton treatment plan
under various situations, multiple dose calculations are required in order to
simulate different setup errors. Recently, researchers have developed methods
which incorporate multiple dose distributions under different setup and range
errors to derive dose volume histograms (DVHs) or its derivatives in order to
evaluate treatment robustness (80, 81, 82). Similarly, researchers have shown
that multiple dose distributions can be incorporated into treatment planning for
robust plan optimization (83, 84, 85, and 86). All of these methods rely on, in
some way, extremely boundary condition. In order to save computation time, it
was suggested that they only calculate dose under extreme condition and create
theoretical worst-case dose distribution by sampling the worst possible dose for
individualized voxel and combining them later to give full dose distribution.
However, when we only rely on the worst case dose distributions or any
deviation resulted from it, we tend to over-estimate the true impact of
uncertainties in our ability to deliver intended dose distribution. While such
method would be acceptable for the purpose of comparing two different plans in
order to determine which plan is more robust, it does not provide any insightful
information as to whether or not the plan itself is an acceptable what would be
the most likely dose distribution under the assumed uncertainties. In order to
realistically assesse and quantify the impact of the uncertainties on planned dose
distribution, it requires to look at, not only at the extreme condition, but almost
all possible scenarios as dictated by their statistical nature. However, due to the
computational cost of calculating proton dose distributions under various
circumstances, the clinical feasibility of robust evaluation and optimization are
difficult to implement. For example, if we wish to simulate setup errors of up to
8mm at 2mm intervals isocentrically, this would require a total of 729 dose
calculations. At our institution, for a typical lung plan, this would require well
over 15 hours of computation time. Therefore, robust optimization and
verification can potentially benefit from a fast dose calculation method in order
to include more information.
In this study, we describe a fast range-corrected dose approximation
method. Our method is different from full dose calculation in that we take
advantage of pre-calculated dose distribution in order to predict new dose
distribution when patient tissue density or WET undergoes slight change. This is
motivated by the heuristic observation that perturbation of the WET along the
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beam path pulls the dose profile proximally or distally from the nominal setting
without significantly changing its overall shape. The new dose distribution can
be created by simply shifting the dose profile based on the “iso-WET”along the
beam direction. This equivalent-WEPL based dose correction strategy reduces
both computational time and computer memory requirements and extends its
applicability to include anatomical deformations. We will benchmark the fast
range-corrected dose approximation method against the full dose calculation
using a commercial treatment planning system that is based on the 3D pencil
beam convolution method (87, 88). Furthermore, we will assess the ability of
the dose approximation method to estimate DVH curves.
B. Methods
In principle, the dose to a point can be calculated by summing up all
contributions of doses from individual beamlets. For the sake of computational
efficiency and our purpose, calculation of individual beam is not done again;
rather, we make the assumption that the scattered dose from small changes in the
patient’s anatomy will remain constant and the dose effect is only caused by the
change in the cumulative WET at each voxel along the beam path. Taking
advantage of the full dose calculation at the nominal position, we can
approximate the new dose distribution by shifting dose along the beam path
based on the equivalent WET from the original plan. This process of remapping
the dose based on the change in WET can be think of pulling protons range in
and out of the beam direction. This requires that a single full dose calculation is
performed using the planning CT images under the nominal setting.

Figure 4-1 An oval shaped heterogeneity was inserted in the beam path to
simulate anatomical changes. The density of the object varied from 0 HU to
1200 HU in increments of 400 HU. The line dose profiles beyond the start
location of heterogeneity (indicated by the arrow) are pulled proximally towards
the source as the density of the hetergeneity increases according to the effective
change in the WEPL while the rest of the profile proximal to the heterogeneity
remains approximately the same. [Permission to publish this figure was
obtained from the Phys Med Biol]
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In this study, we used the clinically commissioned proton treatment
planning system (Eclipse™, Varian Medical Systems, Inc., Palo Alto, CA,
USA). This dose distribution is referred as the nominal dose distribution (s)
while the dose under the testingsituation is referred as realized dose distribution
(3 . s will be used as a template when we approximate 3 under the influence of
both setup error and anatomical change. It is essential that we define our
coordinate system in beam’s eye view in order as it is most natural way to think
about how proton’s range change in perspective of that traveling protons. We
make the z-axis be the depth along the beam’s axis. A point dose at an arbitrary
coordinate of , >, ? , with (0,0,0) being defined at the isocenter, under nominal
setting can be written ass,=,I .The realized dose to that point can be written as a
function of the patient shift error∆, ∆>, ∆? and change in physical depth (? u ,
giving 3,=,I ∆, ∆>, ∆?, ? u . It should be noted that that ? u is a fundamentally
different quantity than ∆?: ∆? is simple the patient setup deviation whereas ? u is
the location in depth under nominal setting which corresponds to the same WET
for the depth at ? under the realized or testing setting.
For the case of the static dose distribution (i.e. for photon beam), we can
immediately approximate the realized dose to a point as follows:
3,=,I ∆, ∆>, ∆?  sv∆,=v∆=,Iv∆I

(1)

That is essentially same as sampling the adjacent dose as if the whole
dose cloud is shifted according to the setup error. To account for the variant
dose distribution, we assume that the perturbation in WET moves point doses in
physical space according to their WET values in the original plan.
B.1 Approximation under setup error
If setup error occurs, there will be a change in WET due to the misaligned tissue
density along the plane that is perpendicular to the beam’s axis. This will lead
to a difference in WET between the line segments tracing different locations in
space. Therefore, one can write:
3,=,I ∆, ∆>, ? u  sv∆,=v∆=,I w P &xi?, ? u ,

(2)

where? u is given by the following line integral relation
I

Iu

0a 89:, >, ? 3?  0a 89: Z ∆, > Z ∆>, ? 3?.

(3)

The function 89:, >, ? is the relative stopping power ratio from the given CT
data and 9is the effective source position. Simply put, equation (2) approximates
the realized point dose by shifting the ray line geometrically (in the BEV
coordinate) while adjusting the longitudinal dose profile given by that shifted
ray line according to the effective change WEPL from equation (3). In equation
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(2), &xi?, ? u   Iv -/.  is the inverse square factor to compensate for the
loss in protons in a divergent beam with the effective source-to-axis distance
(VSAD).Here, the effect of a patient shift along the direction of the beam axis
(∆?) is ignored (except for the inverse square factor)because physical shift of
patient along the beam direction dose not influence WET.
In general, ? u in equation (3) must be solved by iteratively, and therefore
is the most time consuming process of this method. The computational time can
be decreased by saving the line integral values at different depth with the
corresponding s values in computer memory and referencing them as a look up
table for later uses.
B.2 Approximation under anatomical change
For anatomical deformation without considering the setup error (assuming the
images have been registered together), we can approximate the realized dose as
3,=,I ?y  s,=,I w P &xi?, ? u ,

(4)

where ?y is given by the limit of the following integrals
I

Iw

0a 89:, >, ? 3?  0a 89:]

J ,

>, ? 3?.

(5)

In this case, the realized dose will be a function of the effective change in WET
caused by the anatomical deformation which can be tracked using the new
images (i.e. daily or weekly CT images), which gives the function 89:] J . For
the above formula, the location of the line being integrated is identical since no
setup error is assumed but 89:] J , >, ? is used on the right side of the
equation (4) to account for the anatomical deformation given by the new images.
Finally, the approximation method under setup error and anatomical
deformation can be combined to give a general formulation
3,=,I ∆, ∆>, ?y  sv∆,=v∆=,Iu P &xi?, ? u ,

(6)

where again, ?y is given by the limit of the following integrals
I

Iw

0a 89:, >, ? 3?  0a 89:]

J 

Z ∆, > Z ∆>, ? 3?.

(5)

Below step generalize the algorithm for program implementation described in
this method:
Step 1.Calculate the WEPL to a point along the beam path under the nominal
setting.
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Step 2.Translate beam’s isocenter according to the setup error or introduce new
CT images.
Step 3.Calculate WEPL along the corresponding line segment and locate the
physical point along the depth which has the same WEPL as calculated in Step 1.
Step 4.Correct for inverse square factor based on the original physical location
found in Step 3.
Step 5.Repeat steps 1-4 for all points in the image.

B.3 Validation for selected patient cases
In order to validate our dose approximation method, we compared the dose
distributions calculated using a static dose approximation, our proposed rangecorrected dose approximation, and a full 3D pencil beam convolution method
from our clinical treatment planning system (TPS). In this case, we consider the
TPS calculation to be the gold data. All dose calculations were performed using
a dose grid resolution of 2 P 2 P 2.5 $$W . First, a lung cancer patient was
selected. The patient received 4-dimensional computed tomography (4DCT)
scans for treatment planning and weekly over the course of treatment with a
1mm pixel size and 2.5mm slice thickness over the first 6 weeks (denoted week0
to week6) of treatments. Only the time averaged 4DCT data set is used for all
dose calculations. Treatment plan under nominal setting and all consequent
dose calculations were done on these averaged CT data sets following the
clinical protocol used at our institution (89). In order to subject our method to
the extreme case, the PTV was defined as 5mm uniform expansion of CTV and
we deliberately simulated setup error up to 8mm, exceeding the margin bound. .
For anatomical deformation simulation, the volumes of interest were contoured
by a physician on the planning CT and were deformed to weekly CT data sets
using an in-house developed deformable image registration software (90,
91).The nominal dose was calculated using the planning CT data set with no
assumed setup error via the spot scanning beam delivery method with singlefield optimization (92). The setup error was simulated by shifting the planning
CT images along the Anterior-Posterior direction ±8mm in 2mm intervals. At
each interval, doses were calculated using all three different methods: static dose
approximation, our proposed range-corrected dose approximation, and a full
recalculation with the TPS. For the weekly CT data sets, doses were calculated
using all three different methods after manual alignment of beam’s isocenter
based on the bony anatomy to separate the effect of setup error.
Similarly, we validated the proposed method on a prostate and a head &
neck (HN) patient case with inter-fractional anatomic changes to show the
applicability of the proposed method to these sites as well. The prostate case was
chosen due to a change in the femur position on the day of treatment. The HN
case was chosen because of a substantial change in the nasal air cavity in the
beam path on week 6 of treatment, which was partially due to a head rotation
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and tissue/fluid variation in the nasal cavity. We used a 270° beam angle for the
prostate case, and a 0° beam angle for the HN case.
The overall accuracy of both approximation methods were quantified
through the use of a 3D gamma analysis tool developed in-house with 3% dose
and 3mm distance criteria (93). Furthermore, we quantify the accuracy of the
cDVHs derived using the range-corrected method (The difference is denoted as
∆cDVH).
C. Results
C.1 Dose distribution comparison and 3D gamma analysis
For all cases observed, the magnitude of dose variation increased as setup error
increased in all direction. Also for the lung case, the dose variation was
gradually increased from week0 to week6. But both prostate and HN cases
showed no obvious increment in dose variation over the weeks. Table 4-1
shows % volume change of the tumor related volume (i.e. integrated gross tumor
volume and clinical target volume (IGTV and ICTV), and GTV-50 and CTV-50,
the volumes for the exhale phase of the breathing cycle) for the lung patient over
the course of treatment. The largest variation of the planned dose distribution
amongst all of the simulations was observed when we recalculated dose using
the 6th treatment week’s CT images for both lung and HN cases and the 1st week
CT images for the prostate case.
The difference in dose distribution due to both setup and anatomical
change were noted. Figure 4-2 (a) and (b) compares planned dose distribution
and the realized dose distribution using full dose calculation. The most
significant contributing factor to the change in dose distributions for the lung
case was the patient weight loss and tumor shrinkage. The realized dose
distribution given by the static approximation (Figure 4-2 (c)) fails to adjust for
such a change and thereby significantly underestimates the dose to contralateral
lung. However, the realized dose distribution computed using the rangecorrected method (Figure 4-2(d)) is able to estimate the change in depth
penetration of the proton beam with a reasonable accuracy, displaying visually
similar to the result given by the TPS dose calculation
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Table 4-1The measured volume change of the target volumes of interest
observed in the weekly CT images for the lung case. The structures were
contoured on the planning CT and deformed to the weekly CT images using inhouse deformable image registration software. For the selected patient case, a
reduction of 41% of the gross tumor volume (GTV-T50 and IGTV) and 21% of
the clinical target volume (CTV-T50 and ICTV) was observed.[Permission to
publish this figure was obtained from the Phys Med Biol]
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Figure 4-2The dose distributions for the lung case. (a) The full dose (TPS)
calculation on the lung planning CT (planned dose distribution). (b) The full
dose (TPS) calculation on the lung week6 CT (realized dose distribution). (c)
The static dose approximation on the lung week6 CT. (d) The range corrected
dose approximation on the lung week6 CT.[Permission to publish this figure
was obtained from the Phys Med Biol]

Figure 4-3 shows percentage dose difference maps of the dose
distributions between the full dose recalculation and the static dose
approximation, and the full dose and the range corrected dose approximation.
From this figure it is obvious that the static dose distribution can underestimate
(i.e. or does not account at all) the overshoot of proton beam. But our
approximation method was able to predict the change reasonably well. The
result of the gamma analysis is presented in Table 4-2. The lowest passing rate
was observed at the limit of our simulation ranges (8mm setup errors and lung
6th week). Under the chosen criteria (3% dose and 3mm distance), the range-
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corrected method achieved a 93% passing rate for an 8mm setup error while the
static dose approximation method achieved only an 81% passing rate. For the
weekly CT simulation, the range-corrected method achieved a 86% passing rate
for the 6th week CT while the static dose approximation method achieved only
36% passing rate.The worst passing rate found for the 3D gamma analysis of the
prostate case was 89% and 83% for the range corrected and the static
approximation methods, respectively. Similarly, the worst passing rate found for
the HN case showed 84% and 70% passing rates for range corrected
approximation and static approximation methods respectively.

Figure 4-3 The percent dose difference map on the lung week6 CT between
dose distribution using full calculation and dose distribution using (a) static dose
approximation, (b) range corrected approximation, and (c) the percentage dose
difference histograms for the two difference maps. Red dashed line in the
histogram is derived from (a) while blue solid line is derived from
(b).[Permission to publish this figure was obtained from the Phys Med Biol]
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Table 4-2.The result of the 3D gamma analysis on both the ranged-corrected
approximation and static dose approximation with respect to the full dose (TPS)
calculation under setup error and weekly CT simulations. A passing criteria of 3%
dose difference and 3mm distance-to-distance agreement was used. For the sake
of simplicity, for both prostate and HN cases, only the worst passing rate
observed during weekly simulation is shown (week1 for prostate and week6 for
HN). [Permission to publish this figure was obtained from the Phys Med Biol]
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Figure 4-4 A comparison of the dose calculation results in the presence of
inter-fraction
fraction anatomical changes. The original plan and original anatomy for a
prostate case (top row) and a HN case (bottom row) are shown to the left
column. The dose distributions for th
thee changed anatomy calculated by the
commercial treatment planning system (Eclipse, Varian Medical Systems) are
shown in the middle column, and the dose distributions calculated by the rangerange
corrected dose approximate method are shown to the right, respecti
respectively.
vely.
[Permission to publish this figure was obtained from the Phys Med Biol]
Biol

Figure 4-44 shows the comparison visually. The original plan calculated for the
anatomy in the treatment planning CT image is shown in the left column for
each case; the dose distributions in the changed anatomy (due to inter-fractional
inter
variations) are calculated by the TPS and the dose approximation method in the
right column, respectively. It can be seen that the range
range-corrected
corrected dose
approximation method did a reasonable job overall. Most differences are seen in
regions with sharp change in WET. In these regions, more accurate modeling of
lateral scatter appears to be important.
C.2 DVHs comparisons
The change in the planned dose distribution due to both setup and anatomical
deformation resulted in variation of cDVHs derived from realized
realiz
dose
distributions. Figure 44-5 compares the DVH-bands
bands (the area enclosed by the
envelope of the cDVHs) of various structures using full dose calculation and
different dose approxi
approximation
mation methods. The overall shape of the DVH-bands
DVH
derived using range
range-corrected
corrected method closely resembled the DVH-bands
DVH
derived using the full dose calculation while the DVH
DVH-bands
bands derived using static
method mostly under estimated the thickness of the ban
bands
ds for the CTV and other
structures (except for the esophagus under setup error simulation). It is clearly
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shown that the static dose approximation completely failed to account for the
decrease in dose to the target volume and increase in dose to the left lung and
esophagus. Table 4-3 lists the RMS and the maximum difference from the
∆cDVH. Overall, the RMS deviation and maximum difference were larger for
the CTV and esophagus than for other structures due to their small volume size
and their position near the high dose gradient. For the lung case, the largest of
the RMS deviation found were within 2% for both the setup and weekly
simulation. The largest of the maximum differences were found to be within 4%
and 8% for setup and weekly simulation, respectively. The average of the
maximum differences over all simulations was found to be 1.5% and 2.6% for
setup and weekly simulation, respectively for the lung case.

Figure 4-5ThecDVHs of the CTV (red), involved lung (dark blue), contralateral
lung (light blue), and esophagus (black) derived from realized dose distributions
under various setup error (top row) and weekly imaging (bottom row) using
static approximation (a, d), full dose calculation (b, e), and range-corrected
approximation methods (c, f). The thicker lines indicate original DVHs derived
from the planned dose distribution. [Permission to publish this figure was
obtained from the Phys Med Biol]
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Table 4-3 The root mean square (RMS) deviations between the cumulative
DVHs derived using a full dose (TPS) calculation and range-corrected dose
approximation method under various simulations. The first two tables are from
setup error (in Anterior-Posterior direction) and weekly simulations of lung
patient. For the sake of simplicity, for both prostate and HN cases, only the
worst passing rate observed during weekly simulation is shown (week1 for
prostate and week6 for HN). [Permission to publish this figure was obtained
from the Phys Med Biol]

D. Discussion
The main purpose of this fast proton dose approximation was to be able
to roughly estimate the realize dose distribution under the influence of both
setup and range uncertainties caused either by the inherent range or anatomical
deformation in patient. In chapter 4, we demonstrated how statistical mean or
standard deviation can be used to show robustness of a given plan. When
computing such parameters that are computed based on the large number
average (i.e. order of couple hundreds), each sampled calculation does not need
to be so accurate to compute the averaged quantity accurately: standard
deviation of sampled mean is inversely proportional to the square root of the
sample numbers. While the proposed method does not give a sufficient accuracy
for treatment planning and quality assurance, it can be used for gauging a plan’s
sensitivity to setup and range error, for intermediate dose calculations during
plan optimization, or for on-line assessment of major dosimetric impacts. For
this reason, it may be sufficient for such important applications.
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Our choice to use the 3D gamma analysiswas to demonstrate that the
approximated dose distribution is spatially comparable to the full dose
calculation. The overall accuracy in terms of percentage passing rate presented
in table 4-2 depends heavily on the choice of passing criteria. In this work, we
selected a 3% dose difference and 3mm distance-to-agreement criteria and found
that the average passing rate was 93% and 89% for setup errors and anatomical
change. The 3% dose 3mm criteria was chosen arbitrarily and the question of
what criteria to be used and what the minimum passing rate should be
considered acceptable would depend on the nature of applications.
Aside from the actual dose distribution itself, we also measured the
accuracy of DVHs derived using the approximated dose. This is highly relevant
to the application of the proposed method since when evaluating the robustness
of a plan or the dose on the day of treatment, it is necessary to summarize the
multiple 3D dose distributions into 2D dosimetric information such as DVHbands. Previously, Cho et al. (10) discussed the clinical recommendations on
accuracy of DVH curves. Based on the assumption that the point dose accuracy
of 2-4% is clinically tolerable, the RMS of the difference in relative dose
between two cDVH should be less than 1-2%. This RMS criterion measures
overall accuracy of the cDVH curve and permits certain dose bins to deviate
more than the 2%, while still being clinically acceptable. From our experience,
this can happen if the OAR is small or is situated near the beam penumbra and
high dose gradient. For the proposed method, table 4-3 shows that RMS
deviation is well within 2% for all simulations considered except for the rightoptic nerve and left parotid from H&N case.
It’s worth mentioning that our test cases were should be considered the
worst case scenario. In the lung case, the choice of the single lateral beam
arrangement maximized the dosimetric effect of anatomical changes. We
selected this case to test if our dose approximation method can do well in the
presence of significant anatomical changes. In a typical clinical plan where
multiple beam arrangement is used, the magnitude of error in inaccuracy of our
approximation method would scale down. We also challenged the proposed
method using a prostate and a HN case. Both cases had a relatively large change
in anatomy that would affect the proton beam delivery for these sites. The
results were similar to the ones found for the lung case (See table4-2 and table
4-3).
In our current implementation, we only used a single CPU for dose
calculation, which already can achieve the calculation speed of around one
second. Further reduction of computation time can be realized because the
proposed method allows for parallel calculation of using independent beamlets
or ray-tracing lines. We expect that the implementation of this application in
multi-core environment would increase the computation time greatly.
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One of the limitations of the proposed method is that it does not consider
change in scattered dose separately from the primary dose when mapping the
pre-calculated nominal dose. Also, the ray-casting of proton tracks are done in
parallel rather than divergence. The errors resulting from this simplification will
be more pronounced for greater displacement of setup error and near regions
with a sharp gradient of tissue density change lateral to the beam direction. The
pencil-beam based dose calculation algorithm used in Eclipse treatment
planning system is also not perfect in modeling the lateral scatter under complex
geometries or heterogeneities. A montecarlo based dose calculation would
produce more accurate assessment of the proposed method.
E. Conclusion
In order to expedite robust plan evaluation or optimization process, a simple and
fast proton dose approximation method was introduced. The proposed method
takes advantage of the pre-calculated planned dose distribution when
approximating a new dose distribution by correcting the difference in proton
range under setup error or anatomical deformation given by the new set of CT
images. The accuracy of the range-corrected method was shown to be superior
to the static dose approximation method. The proposed method could be used
for robust evaluation, robust optimization, and on-line treatment assessment.
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CHAPTER 5: STATISTICAL ROBUST PLAN EVALUATION
A. Introduction
In radiotherapy, once a treatment plan has been determined, it must be carefully
assessed beforetreatment can be approved. Conventional plan assessment includes
checking dose distribution quality (e.g., conformity, homogeneity, and cold or hot spots)
by overlaying the 3D dose distribution on patient anatomical images. The information
contained in the 3D data is too complex and voluminous for the practical purposes of
prescribing, reporting, and checking the plan. To mitigate this problem, current clinical
practice includes, in addition to 3D dose distribution confirmation, theuse of volumespecific metrics,such as the mean dose of a volume of interest (VOI)andits dose-volume
histogram (DVH)or derived quantities (e.g.,i. : the volume receiving at least dose s).
However, the dose distribution and DVHrepresent a nominal situation that does not
account for the uncertainties associated with the beam delivery process. Dose
uncertainty can be caused by dose calculation inaccuracy(94), estimated stopping
poweruncertainty(95),

daily

interfractionalandintrafractional

patient
anatomy

set-up
and

motion

fluctuation(96),and
changes(97).These

uncertaintiesmake it difficult to accurately assess plan robustnessin proton and
conventional photon therapy.Thus, a geometrically expanded volume that is used for
beam design, such as a planning target volume (PTV),is used for treatment
evaluation.For example, under the assumption that dose distribution is static in space
and the extent of motion of the clinical target volume (CTV) is contained within the
margin added to create the PTV, PTV coverage can be considered an underestimate of
CTV coverage(98). For this reason, PTV is often usedin prescribing and reporting rather
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than the CTV itself(98). The assumption that dose distribution is static in space is
crucial for such interpretation. However, a previous study revealed that this assumption
does not apply to protons because of their sensitivity in range to the density variationin
the beam path(99).Therefore, the paradigm of using PTV as a surrogate for CTV under
uncertainty does not translate well to proton therapy.
Recently, researchers reported evaluation methods that account for both set-up
and range uncertainty in an effort to assess robustness directly. Lomax et
al.(100)proposed the useof worst-case dose distribution and DVHs that are derived from
dose distributionscalculatedunderextreme conditions. Albertinietal.(101)proposed the
use of an error-volume histogram that describes the variation in the point dose of 3D
information as simpler 2Dinformation.Trofimovetal.(102)proposed the use the
DVHbands to visualize the range of DVH variation under uncertainties.However, these
methods rely on dose distributions calculated under a handful of extreme conditions (i.e.,
6 calculations for set-up errors and2 calculations for underestimated and overestimated
range errors). Although these methods are fast and convenientmeans of comparing the
robustness of two different plans, the metrics used are generally too conservative or
even unrealistic and lacks statistical interpretations. On the other hand, Maleikeet al.
(103) and Henriquezet al.(104)proposed methods that fully characterize the probability
density function (js{)of individual point dose distributions.However, their studieswere
limited to dose variations caused by predefined organ motionmodels (103)
anddosecalculationinaccuracies (104).Using statistical methods to characterize dose
uncertaintiescaused by set-up and proton range errors is difficult because the js{ of a
point dose distribution under such uncertainties is not known. To our knowledge, no
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studieshaveperformedacomprehensive statistical analysis of the effectsof set-up and
range uncertainties on proton plans.Therefore, in this study, we proposed and
implemented a practical method to evaluateproton plan robustnessthat is based onwellknown statistical parameters such as expectation values and sampled standard
deviations.
B. Methods
B.1 Patient selection and treatment planning
We retrospectively evaluated the passively scattered beam proton therapy plans of 15
lung cancer patients who were randomly selected from the randomized trial protocol
group of patients who had been treated in the past year at our institution. Their
treatment plans had been developed usingthe following planning objectives: | 99% of
the PTV receiving | 95% of the prescribed dose (i.e., 14 patients prescribed to 74Gy
and 1 patient to 60Gy); total lung i5p= of q 37%; mean lung dose ofq 22Gy; as low as
possible doses to the esophagus iYrp= andirp= and heart iY5p= and iW5p= ; and maximum
spinal cord dose ofq 50Gy. It should be noted that 3 out of 15 treatment plans were not
met with the PTV coverage criteria due to the limit imposed by other organs at risk but
approved for treatment under physician’s discretion. On the basis of the 4DCT data,
each gross tumor volume at individual phases was used to develop the integrated gross
tumor volume, and this was further expanded to become the integratedCTV (ICTV).The
uncertainty in the proton range was addressed by adding a margin equivalent to 3.5% of
the total water equivalent path length to both the proximal and distalICTV surfaces
along the beam path. The uncertainty in the set-up position was considered by
expanding the beam-specific aperture laterally with respect to the ICTV in the beam’s
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eye view.The tissue density change along the beam path as a result of the set-up error
was accounted by smearing the local depth of the compensator. A nominal dose was
calculated on an averaged 4DCT image set. For the purpose of conventional plan
evaluation, a PTV was created by expanding ICTV with 5-mm margins. A more
detailed description of the treatment planning procedure used at our institution and in
this study can be found elsewhere(105).
B.2 Statistics and simulation
A VOI consisted of smaller volume elements or voxels (total number,  . A dose to the
lvoxel(d )was considered a random variable (3d . If thejs{ of 3d (js{d ) for all  is
known, the expectation value of DVH or "siL can be derived by the weighted sum
of the probability of a given voxel receiving a certain dose level.For the sake of
convenience, the framework and definition used in (104) are repeated here in brief.
DVH is defined as siL  ∑d 7d d , where 7d is 1 if3d | ; otherwise, it is 0.
When we use an expectation value operator, we get"siL    "∑d 7d d  
∑d "7d  d . Because 7d can be considered a Bernoulli random variable,"7d  is
equal to j3d |k], which turns the above equation into
"siL   ∑d j 3d |  d  ∑d 0 js{d  3 d .
∞

(1)

To proceed further,we must determinethejs{d .Even thoughthejs{d isunknown, it can
be closely approximated from extensive sampling of point dose values.Acumulative
dose of a treatment course that consists of multiple fractions is considered one sample
dose distribution. To archive the samples, systematic setup errors ∆a , ∆>a , ∆?a were
randomly drawn from a Gaussian distribution function with the mean at the planning
isocenter and the standard deviation equal to 2mm in all , >, and ? directions. Similarly,
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random setup errors ∆C , ∆>C , ∆?C were randomly drawn from Gaussian distribution
function but with its mean at the shifted error position given by ∆a , ∆>a , ∆?a . The
systematic error varied over the courses but was fixed over the fractions within a
course.The random set-up error varied over all fractions. Asystematic range error that
varied over the courses was alsodrawn from the Gaussian function, with a standard
deviation equal to 1.5% of the nominal CT number-to-stopping power ratio calibration
curve.In this study, 60 treatment courses (i.e. a course is composed of multiple fractions)
are simulated for each patient; each treatment course consists of 10 daily fractions that
comprise 600 dose distributions. Although, the actual treatment course consisted of 37
fractions, in our preliminary study,in which we evaluated the convergence of the
"siL as a function of the number of simulations of treatment courses and fractions,
we found that the influence of the uncertainty over the fractions converged when 60
treatment courses comprised of 10 fractions are simulated. (See figure 5-1).
Despite the imposed limit on simulation counts, 600 dose calculations per given
plan

is

too

time

consuming

and

computationally

expansive

forpractical

settings.Therefore, dose distributions were approximated using a validatedfast dose
calculation method(106). The fast dose calculation method approximates proton dose
from original dose distribution under perturbation of radiological path length caused by
set-up isocenter and CT image change. For the sake of continuity of this chapter, we
postpone the detail description of the fast proton dose calculation used in this method to
next chapter (see Chapter 4).
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Figure 5-1 A selected case was pre-evaluated to determine the appropriate number of
courses andfractions. The "siL was computed while increasing the number of
simulations counts, and the maximum difference from the previously calculated
"siL was recorded. (a) After approximately 10fractions the maximum deviation was
contained within 1%. (b) Similarly, after approximately 60 fractions (i.e. each fraction
consisted of 10 fractions) the maximum deviation was contained within 1%. To give a
conservative estimate, the ICTV and esophagus were chosen because the DVHs of both
structures are sensitive to the considered uncertainty;its position near high dose gradient
and its smaller volume size respectively.

On the basis of these sample dose distributions, the integration of js{d in
equation (1) was closely approximated to computethe"siL of various VOIs. The
standard deviation of DVH or KssiL was estimated using the following definition of
sample standard deviation:



KssiL   ] ∑]
dsiLd   "siL  ,

(2)

Wherex is the number of sampled dose distributions over the courses (x  60 .We
compared the DVH under nominal setting (xsiL) against "siL to assess if what
you see on the treatment plan is what you would get under the influence of uncertainties.
Furthermore, we plotted the area extended by all DVHs from 60 simulated treatment
courses (hsiL and from 600 simulated fractions ({siL) to gauge the difference
between the variation of realizable DVHs over treatment courses against the variance of
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DVHs over single daily fractions. A sample distribution of both setup errors in 3D
scatter plot and randomly generated CT calibration curve is shown in figure 5-2.

Figure 5-2 (a) The scattered plot of random and systematic setup errors and (b)
systematic range error calibration curves randomly sampled from Gaussian
distributions.

B.2 Probability map of risk
Above method predominantly addresses uncertainties in DVHs or volumetric
parameters.However, a thorough plan assessment involves spatially confirming dose
distribution.To spatially visualize dose uncertainty, we implemented a similar
method,described by Maleikeet al (103). We visualized the probability of a given voxel
not meeting the clinical goal (i.e. risk). For example, the probability map of risk can
show precisely which voxels in the ICTV willnot likely meet the prescription dose
under uncertainties;these probabilities can be displayed as a heat map, overlaid on the
CT images.The probability of risk for voxel d is calculated using the js{d which was
approximated from 600 sampled dose distributions (see figure 5-7). For example, the
probability of risk for a voxel within an organ is calculated by integrating the
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approximated js{ with its limit of integral defined by the dosimetric objectives of that
organ.
The plan robustness evaluation software, which comprised all the methods
mentioned in this section, was implemented as a plug-in module to the CERR treatment
planning system (107) (version 4.0,beta 2) on an Intel Xeon X5680 3.33 GHz CPUbased computer. The computation time for one patient was approximately 15-20
minutes.
C. Results
C.1 DVH and volumetric parameter assessment
For each patient, we visualized and quantified the variation in DVHs that resultedfrom
set-up and range uncertainties. In all cases, the area extended by the {siLwas much
larger than that covered by the hsiL as shownin figure 5-3 through 5-5 for the ITV,
both lungs, and other organs at risk respectively.This was expected because over the
treatment course, errors from random set-up uncertainties tend to averageout and when
the cumulative dose is calculated by summing over the fractional doses, the extent of
the random setup error was significantly reduced.
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Figure 5-3 Overall robustness of the treatment plan under uncertainty was assessed by
comparing the DVH under nominal setting ( xsiL or dash red line) with its
expectation value ("siL or dash blue line) or standard deviation (KssiL or blue
band). The area extended by DVH variations over the realizable treatment courses
(hsiL or dark gray area) and the area extended by DVH of single fractional cases
whose lower bound closely approximates the worst-case scenario ({siL or lighter
gray area) are also compared.
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Figure 5-4 See the legend from figure 4-3. Shown here are the two lungs.
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Figure 5-5 See the legend from figure 4-3. Shown here are the esophagus, spinal cord,
and heart.
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Furthermore, "siL, which represents the best possible estimateof the true DVH, was
comparedwith the DVH computed under the nominal setting. Figure 4-6 shows the
boxplots of volumetric parameters that were used as constraints during treatment
planning.

Figure 5-6 The effect of uncertainties on the planning parameters (i.e., constraints)
were visualized using box plots that display the smallest, lower quartile, median, upper
quartile, and the largest values observed.
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The statistical assessment of volumetric parameters used during treatment
planning for all 15 patients is summarized in table 5-1. The mean ICTV ip= coverage
under uncertainties was only 1.1% lower than that calculated under the nominal plan. In
cases in which one standard deviation lower than the expected value occurred (i.e.,
corresponding to a 16% chance under the normality assumption), 9 of 15 patientscan be
estimated to receive2% less than in the nominal plan ip= . In particular, patient
1,whohad the largest standard deviation value,would receive approximately 5% less
than in the nominal plan. For the total lung dose, the i5p= and mean lung dose
fluctuationswere less than 1% on average,whereas the esophagus and spinal cord
dosesexperienced substantial fluctuations, with a maximum standard deviation of up to
5% and 5.5Gy for the esophagus irp= and maximum spinal cord dose, respectively.
C.2 Probability map of risk
Probability map of risk was visualized at all slice locations of VOIs. Figure 5-7 shows
the utility of a probability map of risk,which is intended to evaluate the effect of
uncertainties on the plan’s dose distribution, in terms of clinically relevant dosimetric
goals for each VOI.
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Table 5-1 Statistical Analysis of Plan Robustness on 15 Lung Cancer Proton Treatment Plans

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15*
Mean
Max

ICTV

Total lung

 [%]

1.7
0.9
0.2
0.6
0.1
2.4
1.2
0.9
2.2
1.2
0.7
0.6
1.0
1.2
1.2
1.1
2.4

 [%]


0.6
1.0
-0.3
0.7
0.4
0.6
-0.4
0.9
0.1
0.8
-0.1
1.4
0.2
0.9
-0.6
0.9
0.0
0.7
0.0
1.0
-0.8
1.2
-1.0
0.9
0.2
0.4
-0.2
0.9
-3.6
1.2
-0.4
0.9
0.6
1.4


3.1
1.2
0.7
0.6
0.2
1.2
2.1
0.8
2.5
1.4
0.9
0.7
1.0
1.5
1.3
1.3
3.1

Esophagus
MLD [Gy]


-0.3
0.4
-0.4
0.3
0.1
0.3
0.0
0.5
0.1
0.4
0.0
0.7
0.1
0.5
-0.4
0.5
0.1
0.5
-0.4
0.3
0.4
0.6
0.0
0.3
0.2
0.3
0.0
0.6
-1.8
0.6
-0.2
0.5
0.4
0.7

 [%]
   
-5.0
3.2
-2.7
3.4
5.8
3.0
0.6
2.6
0.5
1.8
0.2
2.1
0.2
1.2
0.8
3.0
2.0
2.8
-0.6
1.8
1.7
2.8
1.2
2.0
2.5
1.8
1.9
2.2
4.3
0.6
0.9
2.3
5.8
3.4

Heart
 [%]
   
0.2
1.4
1.1
2.1
6.0
2.0
0.1
0.7
0.6
2.8
0.6
2.2
0.6
0.8
0.9
2.0
1.4
2.1
0.4
1.3
0.7
2.6
0.6
1.6
0.7
2.0
3.0
5.0
0.2
1.0
1.1
2.0
6.0
5.0

 [%]
   
0.0
0.0
0.0
0.0
-0.1
0.6
0.0
0.6
0.0
0.0
0.0
0.0
-0.1
0.4
0.0
0.5
0.1
0.3
-0.1
1.2
0.0
1.5
0.0
0.5
-0.1
0.6
0.4
0.6
0.7
1.6
0.1
0.6
0.7
1.6

 [%]
   
0.0
0.0
0.0
0.4
-0.4
0.7
-0.5
1.2
0.0
0.0
0.0
0.0
-0.7
0.9
-0.1
1.1
0.0
0.6
-0.4
1.7
-0.4
1.8
-0.2
1.0
-0.4
1.2
0.2
0.8
-0.6
1.7
-0.2
0.9
0.2
1.8

Spinal cord
Max dose
[Gy]


0.3
5.3
-0.5
5.2
0.0
2.6
0.5
0.4
0.8
1.5
-1.1
3.2
-4.6
4.2
0.6
2.9
0.2
1.6
2.5
3.6
1.5
5.8
-2.0
1.9
0.0
5.1
-1.0
2.7
0.5
4.2
-0.2
3.3
2.5
5.8

Abbreviations: ip= = percent volume receiving dose greater than  >; x  " = the difference between the value calculated under the
nominal setting and its expectation value under uncertainty; MLD = mean lung dose; Ks =sample standard deviation of the expected
value. *Patient no. 15 was prescribed 60Gy instead of 74Gy.
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Figure 5-7 (a) Dose distribution under the nominal setting. (b) Probability map of risk
of the ITV: The chance of voxels in the ICTV not receiving a dose of more than 74Gy is
shown as a color map. The probability of risk for each voxel is calculated by integrating
the approximated js{ curve from zero doses to the dose objective (i.e., 74Gy). The
js{ofthe voxel located in the center of the ICTV with a 0% chance of receiving a lessthan prescription dose is shown in (c), and the voxel at the boundary of the ICTV with
the highest chance of receiving a less-than prescription dose is shown in (d).

D. Discussion
D.1 Interpretation of results
The chief advantages of a statistical method for evaluating plan robustness are:first, its
prediction is more realistic because it considers all possible range of errors, not just
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extreme cases, and use of familiar statistical parameters, such as expectations and
standard deviations of doses and DVHs, rather than a new metric for uncertainty
assessment such as the worst-case DVH (7). Even though, the theoretical worst-case
DVHs were not directly computed in this work, we can consider the lower bound of
{siL as the best estimate of the worst-case scenario. For all 15 patients, the lower
bound of F[DVH] was out of the bound defined by the 3 times the KssiL indicating
that the likelihood of it being realized during actual treatment is very low. The "siL
can be interpreted as the most probable DVH under uncertainties; thus,it is more
suitable for evaluating and reporting plans than is a DVH generated under a nominal
setting. On the other hand, the KssiL can be interpreted as how likely the outcome
will deviate from the "siL;thusitismore appropriate for evaluating the robustness of
the treatment plan. An ideal plan would have"siL value that is close to the clinical
goal and a small KssiLvalue. In our study,the overall "siLof the ICTV for all
patients was close to the prescription dose level, and the standard deviation was mostly
acceptable, demonstrating that our treatment planning procedure and margins provide
robust target coverage. However, both the esophagus and spinal cord showed significant
fluctuation in DVH values under uncertainties. The KssiL ofthe irp= of esophagus
and maximum spinal cord dose were 5% and 5.8Gy, respectively. Even though, the
theoretical worst-case DVHs (7) were not directly computed in this work, we can
consider the lower bound of {siL as the best estimate of the worst-case scenario.
For all 15 patients, the lower bound of F[DVH] was well out of the bound defined by
the 3 times the KssiL meaning that the likelihood of it being realized during actual
treatment is less than 1%.
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D.2 Geometric PTV and ICTV coverage
Despite the known limitations of PTV,which were discussed in the Introduction, we
found that the original PTV coverage (ip= of PTV under the nominal setting was a
good indicator of how well the ICTV coverage can be retained under uncertainties
suggesting that there still is a merit to defining PTV and using it for plan evaluation for
proton therapy using passively scattered or single field uniform dose optimized plan.
Figure 5-8 shows the relationship between the original PTV coverage and the difference
in ICTV coverage under the nominal setting and its expectation value for all 15 patients.

Figure 5-8 The ICTV coverage difference between the nominal plan and its expectation
value under uncertaintieswas plotted against the original PTV coverage (blue).
Similarly, the standard deviation of the ICTV coverage under uncertaintieswas plotted
against the original PTV coverage (red).

A similar relationship was found for the standard deviation of ICTV coverage under
uncertainties. As shown in the graph in figure 5-8, 95% PTV coverage under nominal
settingsallow a 1% fall-off in ICTV coverage, with a standard deviation of
approximately 1% under uncertainties. Negative slopes of the fitted line of both the
difference in ICTV coverage and its standard deviation indicate that there is a strong
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correlation between the original PTV coverage and the plan robustness.
D.3 Application in head and neck scanning beam proton therapy: a case study
Even though we demonstrated the efficacy of the proposed method using passively
scattered beam plans, the method can easily use for single-field uniform dose (SFUD)
optimized scanning beam proton therapy, with no modifications. An example of a twobeam intensity-modulated proton therapy plan ofachordoma case is shown in figure 59.Of note,because of the high dose-to-CTV conformity, the probability map of risk
shows a significant risk of achieving the clinical goal on the boundary between the CTV
and the brainstem in terms of its probability.
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Figure 5-9 (a) Nominal dose distribution of a two-field SFUD plan in which the CTV
(dark green) is adjacent to the brainstem (light green). Probability map of risk for the
CTV (b) and brainstem (c): the color map shows the chance of the voxel receiving lessthan the prescription dose (66Gy) for the CTV and morethan the dose limit (50Gy) for
the brainstem.

D.4 Limitation
The limitation of this study was that we did not consider intrafractional and
interfractionalchanges in anatomy. The breathing motions and anatomical deformations
over the course of treatment, in response to radiotherapy, can lead to deteriorationsin
the planned dose distribution. In theory, our method can incorporate the uncertainties
associated with breathing motion by using different phases of the 4DCT data set to
formulate a more comprehensive js{of point dose distributions. However, anatomical
changes over the course of treatment are difficult to predict and remain a challenge for
any method of evaluatingtheeffects of uncertaintieson planned dose distribution prior to
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treatment.
E. Conclusions
In this study, we demonstrated that our statistical method of evaluating the effectsof
uncertainty on DVH and dose distribution is feasible.Our method quantifies the
variations in dosimetric parameters in terms of expectation values and standard
deviations. In addition, the uncertainty in 3D dose distribution was evaluated using the
probability map of risk. The proposed method was used to evaluate 15 lung cancer
passively scattered beam proton therapy cases to validate treatment planning procedures
and margins. We found that the current treatment planning procedure,using a passively
scattered proton beam,was robust in terms of maintaining target coverage under set-up
and range uncertainties. However, we also found that the dose to the esophagus and
spinal cord variedsignificantly from the planning dose. The information provided by
this statistical assessmentofuncertaintieswillhelp us make better clinical decisionsfor
plan approval and review.
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CHAPTER 6: PLAN ROBUSTNESS COMPARISON: PROTON THERAPY VS.
IMRT
A.Introduction
In this chapter we apply the robust plan evaluation method developed in chapter 5 to
compare plan robustness of proton therapy and intensity-modulated radiotherapy
(IMRT). Currently, comparison study of proton therapy with IMRT is receiving a lot of
attention in radiation oncology community. As the number of proton facilities increases
there’s been a call for more comparison study between proton and IMRT to justify the
cost and effectiveness of proton therapy (108, 109, and 110). A fair amount of studies
that compares proton and IMRT has been published in recent years (111, 112, 113, 114,
115, 116, and 117). However, it is interesting that most of these studies are purely based
on plan comparisons. A plan comparison study is where two treatment plans, ideally of
different modality or different method of plan design, are compared side by side in
terms of their target coverage, dose conformity, dose uniformity, and dose to critical
structures or normal tissue. Although, treatment plan comparison is arguably the most
widely accepted form of study when one tries to investigate the superiority of a
particular treatment modality over the other, it carries certain risks of not being able to
judge the two plans fairly when considering the effect of uncertainties in beam delivery
process that are not well represented in the treatment plans at the time of assessment.
Such risk is much greater when one tries to compare two modalities that show different
sensitivity to the uncertainties as in proton therapy and IMRT. In chapter 2 showed that
the sensitivity of proton planned dose distribution to the setup, internal motion, and
anatomical change is greater than the conventional photon dose because the range of
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proton is essentially determined by the tissue density along the beam path (118). On the
other hand, for photon therapy, in most of the time, one can safely assume the planned
dose distribution remains static under the small perturbation of tissue density from setup
and anatomical deformation (119). This suggests that, when comparing proton plan
against IMRT plan, one must account for the fact that the two different modalities
behave very differently under the uncertainties. In other words, a fair comparison of
proton vs. IMRT study must consist of uncertainty analysis. Up to this point, there is not
readily available method to objectively compare the plans from two arms. Most studies
however, employee the planning target volume (PTV) coverage as one of the constraint
when designing a plan and by matching the PTV coverage to be identical for both arms,
it is wrongly assumed that the plans are equally robust to the uncertainties. In this
chapter, in order to evaluate plan’s robustness for both arms fairly, we propose to use
statistical parameters such as expectation value and standard deviation of dose
objectives and dose-volume histograms of the clinical target volume (CTV) and other
organs at risk (OAR) directly.
B. Methods
For this study, a group of 15 non-small cell lung cancer (NSCLC) patients who were
randomly selected from the patient population who are enrolled in IMRT vs. Proton
randomized trial at our institution (i.e. in fact, these are the identical patients that were
used in chapter 5). For each of these 15 patients, both IRMT and proton plans were
created under the identical objectives as follow: : | 99% of the PTV receiving| 95% of
the prescribed dose (i.e., 14 patients prescribed to 74Gy and 1 patient to 60Gy); total
lung i5p= of q 37%; mean lung dose of q 22Gy; as low as possible doses to the
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esophagus iYrp= andirp= and heart iY5p= and iW5p= ; and maximum spinal cord dose
ofq 50Gy. The detail description of plan design method based on the 4DCT simulation
was described already in chapter 5. For each of these plans, total of 600 dose
calculations were performed that simulated 60 virtual courses of treatments with each
course having 10 fractions (see figure 6-1). We choose to simulate a treatment course
with only 10 fractions even though our clinical protocol has 36 fractions because we
found that roughly 10 fractions were enough to estimate the final accumulated dose
distribution from the normally distributed random setup errors. A random setup error
was introduced over the multiple fractions while a systematic setup error and a
systematic range error were introduced over the different courses of treatments. The
systematic setup errors were sampled from the assumed Gaussian function with mean
position at the isocenter of treatment planning simulation and with standard deviation of
2mm. The random setup errors were also sampled from the assumed Gaussian function
but with mean position at the position defined by the systematic setup error and with
standard deviation of 2mm. In other words, the random setup error was implied on top
of the assumed systematic setup error already in place. The systematic range error was
introduced by introducing new relative stopping power to CT Hounsfield calibration
curves that are generated by random scaling factor. The random scaling factors were
sampled from the assumed Gaussian function with mean at zero and standard deviation
of 1.5% of the relative stopping power. Due to the Gaussian nature of these simulation
parameters, it can be said that roughly 95% of time, our simulated random and
systematic setup errors were within 4mm, while range error were within 3%. This
agrees well with our current treatment planning practice (120, 121). In calculating doses
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under different simulating parameters, we assumed static dose distribution for IMRT
plans. That is, the dose distribution calculated under nominal setting was simply moved
in physical space over the patient anatomy as we introduced setup errors. The inherent
range error due to the uncertainties in the calibration curve was ignored. Although there
is a small effect of CT HU uncertainties on the photon dose distribution, its magnitude
is much less than the magnitude caused by setup errors (122, 123). On the other hand,
for proton plans, a new dose calculation was performed for every simulation using the
fast dose calculation method described in chapter 4 (124). This is because, for proton
dose distribution, the uncertainties in the relative stopping power to CT HU calibration
curve cannot be ignored. For each simulation data, we computed expectation value of
DVHs (E[DVH]) and compare it to the value given under nominal setting (N[DVH]).
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Figure 6-1 Schematics of patient simulation method. Both IMRT and proton plans were
created and approved for a selected patient. Each of these plans then was used to
calculate dose distributions under varying simulation parameters (i.e. setup position and
different calibration
alibration curve).
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C. Results
Both PTV and ITV coverage under nominal setting were similar between IMRT and
proton plans as can be seen from figure 6-2. The average V74Gy for PTV and ITV for
IMRT plans were 93% (2.5%) and 99% (1%) respectively. The average V74Gy for
PTV and ITV for proton plans were 92% (4.5%) and 99% (1.7%) respectively.
Overall, the difference between the dose objectives calculated under nominal setting
and its expectation values were larger for proton plans. All patients regardless of the
modalities, the expectation value of V74Gy coverage were lower than the value
calculated under nominal setting indicating that the simulated uncertainties always
degrades the intended target coverage. Such difference was observed to be bigger for
proton plans (p-value = 0.0245). The averaged target coverage fall off (i.e. V74Gy) was
-0.4% and -0.1% for proton and IMRT plans respectively. Figure 6-3 through 6-9
compares the variation of the difference observed for all patients between proton and
IMRT in box plots. For both V20gy and MLD of lung, there was no significant
difference between IMRT and proton plans. For esophagus V65Gy dose objective, there
was no significant difference, but for esophagus V45Gy, the difference was observed to
be bigger for proton plans (p-value = 0.045). For heart V30Gy, the difference was
observed to be bigger for IMRT plans but (p-value = 0.035). For the maximum spinal
cord dose, the difference was not statistically significant.
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Figure 6-2 The target coverage in terms of percent volume of PTV (top) and ITV
(bottom) receiving the prescription dose of 74Gy under nominal setting. Both IMRT
and proton plans are fairly identical in terms of planned target coverage.
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Figure 6-3 Comparison of the boxplot of the difference in ITV V74Gy coverage
between the nominal setting and its expectation value sampled from over 600 dose
approximations of all 15 patients.

Figure 6-4 Comparison of the boxplot of the difference in Lung V20Gy coverage
between the nominal setting and its expectation value sampled from over 600 dose
approximations of all 15 patients.
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Figure 6-5 Comparison of the boxplot of the difference in mean lung dose (MLD) Gy
coverage between the nominal setting and its expectation value sampled from over 600
dose approximations of all 15 patients.

Figure 6-6 Comparison of the boxplot of the difference in Esophagus V65Gy coverage
between the nominal setting and its expectation value sampled from over 600 dose
approximations of all 15 patients.
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Figure 6-7 Comparison of the boxplot of the difference in Esophagus V45Gy coverage
between the nominal setting and its expectation value sampled from over 600 dose
approximations of all 15 patients.

Figure 6-8 Comparison of the boxplot of the difference in Esophagus V65Gy coverage
between the nominal setting and its expectation value sampled from over 600 dose
approximations of all 15 patients.
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Figure 6-9 Comparison of the boxplot of the difference in Spinal cord max dose Gy
coverage between the nominal setting and its expectation value sampled from over 600
dose approximations of all 15 patients.
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D. Discussion
Despite the difference in the magnitude of change when we compare the dose objectives
under uncertainties, all plans from both arms achieved the initial dose objectives
indicating that the current treatment plan design method was adequate enough to
account for the simulated uncertainties. However, it was found that proton plans were
slightly more sensitive to the uncertainties when compare to IMRT plans.
E. Conclusion
We showed that the statistical parameter such as the expectation value can be used to
assess the influence of uncertainties dosimetric parameters. Since this method can apply
to both IMRT and proton plans, it was used to assess and compare overall robustness of
a given treatment plan for IMRT and proton for 15 lung cancer patients. Except for
heart dose, all other dose objectives were better retained in IMRT plans than proton
plans.
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CHAPTER 7: Conclusions of Dissertation
A. Conclusions of Hypothesis 1
Hypothesis 1: A plan treated to a Beam-specific planning target volume (bsPTV)
can minimize the loss of target coverage due to setup and range uncertainties when
compared to a plan treated to a conventional planning target volume (PTV).
The concept of bsPTV for accounting setup, internal motion, and inherent range error
for proton therapy was proven useful in chapter 3. Our implementation of bsPTV was
novel in that it took into account the tissue heterogeneity misalignment into distal
margin calculations that was previously only possible with physical compensator
smearing. In our carefully designed control experiment, even under the influence of
extreme setup and range error, bsPTV retained its initial target coverage up to 94%
when the conventional PTV could only retain up to 67%. Therefore, we can conclude
that our hypothesis holds its ground within the realm of our experiment. In investigating
our hypothesis 1, we have developed and implemented a standalone software that
generates bsPTV for a given treatment plan parameters. This software has proven useful
for this project and for others as well. The bsPTV awaits more validation in more
clinical sites such as prostate, lung, and head and neck area. Also, the design method of
bsPTV can be expanded to include the change in tissue density due to breathing motion
by incorporating 4DCT data set.

104

B. Conclusions of Hypothesis 2
Hypothesis 2: Statistical method can be used to accurately quantify the variation in
dose distribution and dose-volume histograms (DVHs) due to setup and range
uncertainties.
The statistical method of quantifying the impact of uncertainties on planned dose
distribution and its DVHs was developed and its application was tested on the selected
lung cancer patients in chapter 5. Based on our current proton treatment planning
procedures for the lung cancer patient, we quantified the expectations and standard
deviationsof volumes of interest for all 15 patients.The mean expectation value of
prescription dose of theintegratedclinical target volumewas 1.1%less than that of the
original coverage, with a standard deviation of 1.0%. The most sensitive organ at risk
was spinal cord with a mean standard deviation of its max dose of 3.3%. Based on the
result of our study, we conclude that the proposed statistical method provides a
quantitative means of realistically assessing dose and DVH.In investigating our
hypothesis 2 we have developed and implemented a standalone software that evaluates
the uncertainties of a given treatment plan. Another significant achievement through
this project was the development of fast range corrected proton dose approximation
method that was discussed in chapter 4. The statistical method of quantifying the
treatment uncertainties is new and therefore currently, we lack the ability to interpret the
result by matching it to our clinical experience. Future challenge would be to establish
the quantification with our previous experience by looking at the relationship between
the magnitude of calculated treatment uncertainties and clinical end points such as dose
toxicity, recurrence rate, and etc.
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